Achondroplasia: a comprehensive clinical review
Achondroplasia is the most common of the skeletal dysplasias that result in marked short stature (dwarfism). Although its clinical and radiologic phenotype has been described for more than 50 years, there is still a great deal to be learned about the medical issues that arise secondary to this diagnosis, the manner in which these are best diagnosed and addressed, and whether preventive strategies can ameliorate the problems that can compromise the health and well being of affected individuals. This review provides both an updated discussion of the care needs of those with achondroplasia and an exploration of the limits of evidence that is available regarding care recommendations, controversies that are currently present, and the many areas of ignorance that remain.
KeywordsAchondroplasia FGFR3 Skeletal dysplasia Natural history Care guidelines
Achondroplasia personal life experiences scale
Bilevel positive airway pressure
Body mass index
C-type Natriuretic Peptide
Continuous positive airway pressure
Fibroblast Growth Factor
Fibroblast Growth Factor Receptor 3 gene
Fibroblast Growth Factor Receptor 3 protein
Magnetic resonance imaging
Natriuretic Peptide Receptor B
Recurrent-autosomal dominant-male biased-paternal age effect
Severe achondroplasia – developmental delay – acanthosis nigricans
Explicit guidelines for care of individuals with achondroplasia are available. Such guidelines were first developed by the American Academy of Pediatrics in 1995 and revised in 2005 . These are now again somewhat out of date. Other care guidelines (for example see [2, 3, 4]) and clinically oriented reviews (such as [5, 6, 7]) are also available. However, none of these explores in detail the bases for recommendations and the uncertainties that exist. Therefore, this review is intended as both an updated discussion of care needs in achondroplasia and a platform for exploration of the evidence for recommendations, current controversies and areas of current ignorance (which are many).
As is the case for virtually all uncommon or rare genetic disorders, the level of evidence for care recommendations in achondroplasia is generally low. No controlled or blinded studies of any sort are available. Very few prospective investigations have been published (such as [8, 9] and a few others). Most care suggestions are based on retrospective series of varying size, or anecdotal information that lacks any rigorous confirmation. Both retrospective studies of large populations and selective prospective studies are much needed. Nonetheless, something has to be recommended for the care of affected individuals. Not surprisingly, lack of rigorous studies also results in considerable variation in the recommendations that are made. Unfortunately, this is not terribly different from much of current medical care. Some of these uncertainties will yield to studies of larger populations, as have been initiated recently .
The achondroplasia phenotype has been recognized for thousands of years, as evidenced in the artifacts of many different cultures , and remains the most readily recognizable of the dwarfing disorders. The term seems to have been first used in the nineteenth century, and, while the main features were described shortly thereafter , it often was used as a generic descriptor of all short-limb dwarfing disorders (in contrast to the short-trunk or Morquio type) for the first half of the twentieth century. Detailed and specific radiologic and clinical features were carefully delineated by Langer et al. . It remains the best characterized and most studied of the hundreds of dwarfing skeletal dysplasias. It is sufficiently common that many pediatricians and family practitioners will help care for one or more individuals in their practices.
Appropriate distinction between this and other short-limb dwarfing disorders was, and remains, crucial, of course. Earlier confusion with thanatophoric dysplasia led to the erroneous conclusion that adults with achondroplasia had risk to have children with a lethal form of achondroplasia; conflating of achondroplasia and recessive short-limb dwarfing processes suggested, incorrectly, that parents of average stature with one child with achondroplasia might have high risk for recurrence.
Birth prevalence has been estimated in a number of populations  (also [14, 15, 16]). These studies yield fairly consistent estimates whether these are population based or hospital based assessments. Together they suggest that achondroplasia arises in about 1 in every 25,000–30,000 individuals. That, in turn, translates into around 250,000 affected persons worldwide .
All instances of achondroplasia arise from mutations that are autosomal dominant. These mutations are fully penetrant and show only modest variability of expression. Because of its dominant inheritance pattern, an individual affected with achondroplasia (and whose partner is of average stature) has a 50% risk for each of their offspring to be similarly affected. However, most instances of achondroplasia – perhaps 80% – arise from new, spontaneous mutations . In turn, then, around 80% of affected babies are born to two unaffected, average statured parents.
One would anticipate that recurrences to average statured parents should be no greater than occurrence in the population as a whole. That does not seem to be the case, however. Quite a number of unexpected instances of recurrence in siblings has been observed [18, 19, 20, 21, 22] (and personal observations). While likely increased, almost certainly that recurrence risk is far less than 1% . The likely molecular explanation for this increased risk is discussed below.
Special considerations regarding recurrence risks
Homozygosity and compound heterozygosity
Assortative mating – that is, greater probability of partnering with an individual with a phenotype similar to one’s own – is particularly common within the community of individuals with dwarfing disorders . Because achondroplasia is much more common than any other dwarfing dysplasia, the most common of such matings is between two individuals both of whom have achondroplasia. As for many other so-called dominant processes, pure dominance (having one abnormal allele or having two such alleles resulting in indistinguishable phenotypes) is not observed. Rather, a ‘double dose’ of the achondroplasia-causing mutation results in a far more severe process . Indeed, homozygous achondroplasia is virtually always lethal in the newborn period . These early deaths probably arise through mechanisms that also place babies with heterozygous achondroplasia at risk – restrictive pulmonary disease and craniocervical junction constriction [24, 25], as discussed below.
Risk for homozygous achondroplasia when both parents have achondroplasia is 25% (as well as there being a 50% chance for heterozygous achondroplasia and 25% chance for a child with average stature). Many at risk couples opt for preimplantation diagnosis or prenatal diagnosis solely to rule out homozygosity, while others may elect adoption (often of small statured individuals).
Hypochondroplasia is a generally somewhat less severe small stature disorder that often is caused by mutation in the same gene as the mutations that result in achondroplasia. If one parent has achondroplasia and one has hypochondroplasia, then there is a 25% risk for a child with compound heterozygosity for both achondroplasia and hypochondroplasia. This results in a very severe phenotype that includes cognitive disability and substantial medical problems [26, 27, 28, 29].
Similarly the result of the aforementioned assortative mating, double heterozygosity may arise when two parents have two different and non-allelic bone dysplasias [30, 31]. Each of these is rare. Each has a distinctive phenotype. Some result in a very poor prognosis (e.g. achondroplasia-SEDC [30, 32, 33], while others may have quite variable outcome (e.g. achondroplasia-pseudoachondroplasia  [and personal observation]). Others may actually result in an ameliorating effect . The possible outcomes are sufficiently complex that formal counseling should be recommended in all such instances.
It shouldn’t come as a surprise that relatively common disorders may co-occur within the same individual. A number of such coincidental co-occurrences have been described in individuals with achondroplasia. Of particular note is the occurrence of achondroplasia plus Down syndrome. It should be expected that this arises on occasion: Down syndrome is more frequent in the offspring of older mothers, while achondroplasia is more common in children of older fathers; and, of course, maternal and paternal ages tend to co-vary. Seven instances have been reported in the literature [36, 37] but there are certainly many more that have not been reported (including three personal observations). Unfortunately, these two disorders have features that, together, can result in very severe problems – hypotonia in both; craniocervical junction issues in both; restrictive pulmonary disease in both. Not surprisingly, then, this combination often results in death in infancy .
Molecular genetics and molecular pathogenesis
Discovery of the molecular cause of achondroplasia
Thousands of years after its recognition, nearly a century after its clinical description, and a quarter century after it clear clinical and radiologic delineation, the molecular basis of achondroplasia was discovered. Shiang et al.  showed that individuals with achondroplasia have identifiable mutations in the fibroblast growth factor receptor type 3 (FGFR3) gene. Rapidly it was demonstrated that nearly all instances of achondroplasia are caused by FGFR3 mutations [39, 40]. This locus homogeneity was not particularly surprising. What was unexpected is that virtually all mutations in FGFR3 arise in the same nucleotide pair and result in the same glycine to arginine substitution (G380R) in the FGFR3 protein . This specific mutation is at least 500- or 1000-fold more frequent than expected [41, 42].
Features of FGFR3
Under “normal” conditions the typical FGFR3 is silent. However, various fibroblast growth factors (FGFs) – principally FGFs 2, 9, 18 and 23  – can act as ligands, binding to the FGFR3 [44, 48], in effect filling the cup. This results in dimerization of the receptors, transphosphorylation and trans-activation of tyrosine kinases, and propagation of an intracellular signal . Although downstream signaling is complex [48, 49], overall the signal within the growth plate of cartilaginous bones is negative. That is, overall FGFR3 is a negative regulator of chondrocytic bone growth (through shortening of the proliferative phase and accelerating terminal differentiation ). The “full cup”, then, results in a net “slow down” signal inside relevant cells.
FGFR3 in achondroplasia
The mutation that results in achondroplasia is a gain of function mutation  rather than an inactivating mutation. It most likely results in ligand independent activation of FGFR3 [50, 51]. This, then, is constitutive activation of an inhibitory signal. Or, one can think of this as a continuous “slow down” signal, released from the usual ligand-based constraints.
Dysplasias can be sorted into families in which members differ mostly by severity . Other disorders within the achondroplasia family (and discussed below) are also caused by different mutations in FGFR3. Severity seems to be a consequence of a graded series of relative activation of FGFR3 [53, 54, 55].
Virtually all of the clinical features and medical problems of achondroplasia arise because of the consequent abnormalities of cartilaginous bone growth – either directly, or because of disproportionate growth of cartilaginous bone compared with nearby structures derived from other tissues.
Origin of the unexpected frequency of the achondroplasia mutation
Why is the mutation resulting in the G380R amino acid substitution so frequent? This is related to the paternal age effect which has already been briefly mentioned. It has been recognized for a long time that certain genetic disorders arising through new mutations occur far more frequently in the offspring of older fathers . That phenomenon is particularly marked in achondroplasia . Both the origin of this paternal age effect and the exceedingly high apparent mutation rate have a single basis [41, 42]. That basis also helps explain why all mutations in sporadic cases of achondroplasia are paternal in origin .
It seems that certain mutant protein products, including of FGFR3, are positively selected for in sperm precursor cells (spermatogonial stem cells). Once such a mutation occurs there will be clonal expansion of cells containing the mutation and consequent enrichment within the spermatogonial population. This positive selection within germinal precursors, rather than an actual increased mutation rate, probably explains the prevalence of achondroplasia. If, as seems to be the case, such selection only occurs in male germinal precursors, this also explains the paternal origin of virtually all instances of achondroplasia. Furthermore, since clonal expansion will cause more and more enrichment with time , fertilization involving a sperm with such a mutation becomes more likely with advancing paternal age. Finally, this also explains why some men have more than one “sporadically” affected child .
Achondroplasia is one of a small number of so-called RAMP disorders – recurrent, autosomal dominant, male biased, paternal age effect disorders – all of which likely arise because of their positive selective effect on spermatogonia. Other disorders for which there is convincing evidence of similar effects include Apert syndrome, Noonan syndrome, and multiple endocrine neoplasia type 2B .
Presentation and diagnosis
Diagnosis in the neonate
The vast majority of individuals with achondroplasia are diagnosed in early infancy, although prenatal recognition has become more frequent and more accurate. It is critical that diagnosis not be delayed since certain complications can only be prevented through assessment in early infancy (see Special Concerns in the Young Infant).
No formal clinical diagnostic criteria have been published, but well defined clinical and radiologic characteristics of achondroplasia  usually allow for virtual certainty. In certain circumstances, particularly in the markedly premature neonate , clinical diagnosis may be especially challenging.
Small stature. Small size is not a constant feature in infants, who may have lengths within the normal range .
Short limbs and rhizomelic disproportion. Rhizomelic (proximal) shortening is uniformly present (at least in the arms [12, 62]), although variable in severity. Often there are redundant skin folds of the upper arms and the thighs.
Macrocephaly. Head size is usually large at birth and remains so throughout life . Variable frontal and parietal bossing (prominence and bumpy protuberance) is usually present (Fig. 3). The anterior fontanel is often large in infancy and may persist to as late as 5 or 6 years of age.
Midfacial retrusion. Underdevelopment of cartilaginous bones of the face result in flattening of the entire midface and a flat nasal bridge, a short nasal spine and anteversion of the nose (Fig. 3).
Small chest. In addition to the chest being often smaller than average , the ribs are overly compliant. This results in paradoxical movement with inspiration, which is often misinterpreted as being retractions reflecting respiratory distress.
Thoracolumbar kyphosis. Virtually all infants develop a dynamic thoracolumbar kyphosis in infancy , but this is not present at birth.
Lumbar hyperlordosis. Exaggerated lordosis (“swayback”) arises when walking begins.
Limited elbow extension. Unlike most other joints, the elbows are stiff and may, with age, become progressively stiffer.
Short fingers and trident configuration of the hands (Fig. 6).
Hypermobile hips and knees.
Bowing of the mesial segment of the legs. Bowing is not congenital. It most often arises in early childhood and may progress at unpredictable rate and extent until growth is completed.
Hypotonia. Most infants with achondroplasia are hypotonic . The combination of joint hypermobility and hypotonia means that many infants will seem particularly “floppy”.
In summary, those features that are diagnostically most helpful in the neonate and young infant include: rhizomelic shortening of the arms; macrocephaly; midfacial hypoplasia and nasal anteversion; small chest; short fingers and trident configuration; hypermobility of the hips and knees; hypotonia. Not all infants will display all of these features.
Diagnostic confirmation requires radiographic assessment. Although achondroplasia is a metaphyseal dysplasia, generalized metaphyseal changes are mild and nonspecific. Diagnostically helpful features include: short, robust tubular (“long”) bones; squared off iliac wings; flat, horizontal acetabula; marked narrowing of the sacrosciatic notch; a characteristic proximal femoral radiolucency; narrowing of the interpediculate distance of the caudal spine (although often not present in the neonate); short proximal and middle phalanges . Typically a complete skeletal survey (or a hemi-survey of one side of the body) will be obtained (Figs. 4 and 5). However, most of the diagnostically critical features will be appreciated on a single anteroposterior radiograph of the pelvis and femora (Fig. 4).
Only rarely should diagnostic uncertainty remain after careful clinical and radiologic assessment. When needed, molecular testing is straightforward. Because nearly all instances of achondroplasia arise from a change in the same base pair of FGFR3 , targeted mutation analysis is the routinely employed molecular test. Around 98% of persons with achondroplasia will have a c.1138G>A gene change, and 1% or so will have a c.1138G>C mutation . Testing is available commercially from a large number of laboratories. Only very rarely and in very unusual circumstances will any additional molecular testing be warranted.
On rare occasions, when molecular confirmation has been sought, a common mutation will not be found. In such an event, further analysis of FGFR3 is warranted , since occasional instances of other FGFR3 pathogenic variants have been documented previously [67, 68, 69, 70, 71]. Note, however, that in some of these there is inadequate clinical documentation [67, 69], while in others such as the case described by Takagi et al.  the phenotype is, in fact, inconsistent with typical achondroplasia.
In the most general sense, any short limb dwarfing disorder would fall within the spectrum of the differential diagnosis of achondroplasia. Only a few conditions are likely to result in any substantial confusion, however.
Nonetheless, occasionally molecular testing is warranted in distinguishing hypochondroplasia and achondroplasia. If a child being assessed clearly has either achondroplasia or hypochondroplasia but it is uncertain which of these is present, the most parsimonious approach is to test for the achondroplasia pathogenic variant first. If it is present, the diagnosis is confirmed. If absent (and since virtually all individuals with achondroplasia have the so-called common mutation) and the child clearly has one or the other of these diagnoses, then a diagnosis of hypochondroplasia can be made. With such a result, hypochondroplasia may have arisen either because of a mutation in FGFR3 or at some other locus, but making that distinction is not nearly so important as making the distinction between achondroplasia and hypochondroplasia.
SADDAN syndrome [92, 93, 94] is most infelicitously named. “SADDAN” stands for “severe achondroplasia with developmental delay and acanthosis nigricans”. It uniformly results from a mutation that causes a Lys650Met substitution in FGFR3. Prior to the age at which developmental disability can be recognized and before acanthosis nigricans develops, confidently differentiating achondroplasia and SADDAN syndrome requires molecular evaluation. Such assessment should be pursued, particularly in instances in which global developmental delays more severe than those typically seen in achondroplasia are identified.
In addition to the FGFR3 family of bone dysplasias, other mutations in this same gene can cause Crouzon syndrome with acanthosis nigricans , Muenke syndrome , isolated acanthosis nigricans with or without slow linear growth [99, 100, 101], and slow linear growth without unequivocal features of a bone dysplasia being present . Loss of function mutations (in contrast to the gain of function that results in achondroplasia) cause an overgrowth disorder in both sheep  and humans .
Achondroplasia is a metaphyseal dysplasia. Generally, however, other metaphyseal dysplasias, such as the Schmid type of metaphyseal dysplasia  and cartilage-hair hypoplasia  are straightforwardly distinguished by clinical features, radiographic features and age of presentation.
Any rhizomelic dwarfing process might occasionally cause diagnostic confusion. Pseudoachondroplasia  deserves mention. Despite its name, it is primarily a spondyloepiphyseal dysplasia sharing little except rhizomelic dwarfism with achondroplasia. It has none of the craniofacial features that are present in achondroplasia. It is typically not diagnosed until the 2nd or 3rd year of life. Radiographs are utterly dissimilar.
Most of those with achondroplasia will have a normal or near normal life expectancy. However, there is an increased risk for premature death [107, 108, 109] related not only to sudden unexpected deaths in infancy (see below) but also, it appears, to cardiovascular complications in mid-adult life . Overall, average life span is about 10 years less than that of the general population . A recently completed study  confirms that the highest standard mortality rates are in those less than 4 years of age. However, in addition, that multicenter mortality study shows that there has been a dramatic decrease in deaths, including sudden unexpected deaths, in young children with achondroplasia, most likely secondary to recognition of their special risks and aggressive evaluation and intervention related to the craniocervical junction .
Natural history and management
Most of the medical issues that need to be addressed in individuals with achondroplasia are presented by organ system, below. However, there are two concerns – craniocervical junction constriction and restrictive pulmonary disease – that may be of major concern very early in infancy. These are summarized here. The first of these is a particularly important reason (along with parental needs) that diagnosis be confirmed as quickly as possible in infancy, so that critical evaluations can be completed in a timely manner.
Special concerns in the young infant: the craniocervical junction
The possibility that infants with achondroplasia are at increased risk for unexpected death was raised as early as 1982 by Pauli & Lebovitz  and Bland & Emery (cases 3 and 5) . The single event that precipitated three-plus decades of investigation is as follows . A baby boy was born to a mother of average stature and a father who had achondroplasia. Aside from achondroplasia, the boy was healthy and thrived until 3 months of age when he was found dead in his crib. He had been neurologically normal and had no antecedent illness. Postmortem assessment found no cause of death and a diagnosis of sudden infant death syndrome (SIDS) was made. The family was counseled that the baby’s achondroplasia and SIDS were almost certainly coincidental and unrelated. A new sister, also with achondroplasia, was born a year later. Not because of any suspicion that SIDS and achondroplasia were linked, but rather because of the then favored notion that there was strong familiality on a genetic basis for SIDS , polysomnography was completed. It showed substantial abnormality of central respiratory control, which abnormalities resulted in two clinical apneic episodes requiring stimulation, but which resolved by 5 months of age.
All of the deaths in the initial report were between 3 and 11 months of age , suggesting that if preventive assessments are to be effective they must be completed early in infancy.
Subsequent experience has clearly demonstrated that without careful assessment some infants with achondroplasia will die because of craniocervical junction issues [8, 118]. A number of studies have provided important additional information. For example, Reid et al.  confirmed that craniocervical compression can cause non-lethal but severe respiratory problems, and that a complex interplay of restrictive, obstructive and centrally caused respiratory issues in infants with achondroplasia can be difficult to sort out in practice. They also showed that the non-lethal respiratory problems were alleviated by suboccipital decompressive surgery . Although the interpretation by Tasker et al.  of their patients’ signs and symptoms are likely in some ways incorrect, they did demonstrate that basicranial hypoplasia seems not only to cause central apnea but can also result in obstructive apnea  (what can be termed centrally mediated obstructive apnea); this might also be the reason for the observations of Sano et al. , which are otherwise inexplicable. Further, Tasker et al. pointed out that gastroesophageal reflux can additionally complicate the picture in infants with achondroplasia .
Estimate of risk
Although the risk of death remains uncertain, consensus has developed that it is substantial. Hecht and her colleagues [107, 108] have estimated that the risk for death in the first year of life may be as high as 7.5%. While that may be a maximal risk and may, indeed, be an overestimate, nonetheless, without special assessment and, when needed, surgical intervention, that risk is likely at least 2–3%. Although there was early disagreement about whether this is a real phenomenon , subsequently a consensus arose (D. Rimoin, personal communication, 2004) at least to the fact that this is a real concern.
Prospective assessment of level of risk and of risk factors
Between 1983 and 1994 we prospectively evaluated 53 infants with achondroplasia who were referred without explicit neurologic or respiratory concerns . Uniform, comprehensive assessments demonstrated that 5 of the 53 had problems of sufficient severity to justify suboccipital decompressive surgery. In every such instance, marked abnormality of the upper cervical cord was demonstrated intraoperatively. Replicable predictors of need for decompression included: (1) small foramen magnum compared with achondroplasia standards ; (2) hyperreflexia and/or clonus; (3) central hypopneic events resulting in oxygen saturations below 0.85 by polysomnography . Therefore, anatomic, neurologic and respiratory characteristics, together, allow identification of those babies who likely are at highest risk to experience life-threatening events related to the craniocervical junction.
Recommended evaluation – standard assessment
As already noted, if any assessment is to make a difference regarding sudden unexpected deaths, it must be completed very early in life, preferably prior to 3 months of age .
▪ Neurologic history and neurologic examination, the latter emphasizing whether there is hypotonia more severe than typical for babies with achondroplasia, and whether hyperreflexia or clonus is demonstrable.
▪ Imaging of the craniocervical junction. Initially this was most often by computerized tomography  (Fig. 13). This approach continues to offer certain advantages. First, it allows measurement of the size of the foramen for which standards are available  and which was a demonstrable predictor of need for decompression . Secondly, most often it can be completed without sedation or anesthesia. This may be a serious consideration given concerns about the effects on synaptogenesis of anesthesia in young babies .
▪ Polysomnography (sleep study). This should be performed in a sleep center comfortable with assessing infants. Interpretation can be complicated by restrictive pulmonary issues with decreased respiratory reserve. Emphasis, of course, should be on assessing central apnea and hypopnea.
Alternative approaches to initial assessment
Various alternatives have been suggested and used. Note that none has prospectively demonstrated utility, but are mostly based on ‘reasonableness’. Such prospective investigations of what evaluation scheme is most helpful are desperately needed but very difficult to develop.
Many centers have elected to proceed directly to MRI rather than CT . Better visualization of neural tissue is forthcoming, but usually sedation or general anesthesia will be needed because of the length of the procedure. Often multiposition MRI is elected [126, 129]. Flow studies may be of some help as well in determining whether surgical intervention is warranted [126, 128]. Three dimensional CT might be another alternative , as might be diffusion tensor MRI imaging . Another alternative that has been considered is so-called fast-MRI (or quick-MRI) . This obviates the need for anesthesia and the possible risks that this entails both immediate and, at least speculatively, long term . However, while sufficient for many purposes, detail obtained by fast-MRI is not sufficient to definitively determine the need for surgery related to the craniocervical junction.
Comparison of advantages and disadvantages of various imaging approaches in young infants with achondroplasia
Usually not requiring sedation
Poor delineation of neural structures
Only study method for which there are diagnosis-specific standards (FM size) 
Substantial radiation exposure, particularly if not performed in children’s facility
Only study method for which prospective assessment of value in ascertaining risk is available 
In substantial minority, along with results of other non-radiologic studies, will lead to MRI subsequently
In our experience, about 20% of those following protocol including CT will go on to MRI
Excellent delineation of neural structures
Virtually always requires sedation or anesthesia
Because of respiratory concerns present in most infants with achondroplasia, anesthesia is usually needed
No radiation exposure
No diagnosis-specific standards
Substantial risk of over-reliance in determining if surgery is needed
Although not prevalent in our center, there are many anecdotes of electing to have decompressive surgery based on MRI craniocervical features alone, which we would judge to be non-actionable without other indications
Fair delineation of neural structures
Detail may be insufficient for decision making
No radiation exposure
No diagnosis-specific standards
No sedation or anesthesia needed
In substantial minority will lead to full MRI before deciding if surgery is needed
At current level of detail, findings on fast MRI will always need to be confirmed by routine MRI if surgery is contemplated
No routine imaging
No sedation or anesthesia
Under-ascertainment of those needing decompression
This is, in my opinion, an unacceptable risk
No radiation exposure
Ignores what prospective and reasonably well controlled trial data as are available to prevent further neurologic injury or sudden death.
Some have also suggested a step-wise protocol. For example, one might only image those children in whom worrisome features are present by clinical examination and/or polysomnography (M. Bober, personal communication 2014). While logical, such stepwise assessment has not yet been rigorously assessed and should not be embraced without evidence to support it. Likewise, the suggestion that polysomnography is not predictive of craniocervical junction concern, and so implying that it is not an essential assessment , is based on a small, retrospective series of patients, of whom many were well outside the age range of relevance, and is not worthy of further consideration.
Somatosensory evoked potentials could be of considerable benefit in identifying infants at high risk. Early experience, however, suggested that most infants with achondroplasia showed abnormalities of somatosensory evoked potentials, and that it failed to discriminate between those at high risk and others . However, other investigations suggest that there may be a role of evoked potentials in the assessment of the craniocervical junction in infants with achondroplasia [138, 139, 140]. Should any prospective studies of efficacy of evaluations be initiated in the future, somatosensory evoked potential testing should probably be included in such a protocol.
Counseling regarding cautions that should be exercised with every infant with achondroplasia are based, in part, on the presumed mechanism of injury at the craniocervical junction and, in part, on the circumstances that have been observed in instances of unexpected infant deaths. As noted, risk likely is related to a combination of foramen magnum constriction, the typically large head of achondroplasia and poor head control, which often takes longer to develop in infants with achondroplasia. Uncontrolled head movement should, then, be avoided. There is anecdotal evidence that deaths are particularly likely to arise in babies who have been placed in vertical automatic swings [4, 113]; in fact, I am aware of at least six instances in which babies with achondroplasia have died in vertical automatic swings. There also have been multiple instances of life-taking or life-threatening events in car seats  (and personal observations).
Careful head and neck support, particularly with transitions.
Prohibition of automatic swings (“swingomatics”).
Use of solid back strollers rather than umbrella strollers that may more forcibly flex the neck.
Use of a neck roll in strollers, and, particularly, in car seats. When restrained, infants with achondroplasia, who have large and prominent occiputs, will have their necks in a forced flexed position.
In those infants where assessment demonstrates unequivocal cord compression resulting in clinical abnormalities, then suboccipital decompression should be completed urgently [142, 143]. Operative intervention may be particularly challenging because of the unique anatomy of the skull in achondroplasia [116, 142].
At major centers in which large numbers of children with achondroplasia are evaluated, most report a decompressive surgery rate in infants of around 10% (11% ; 8% [145, 146]; 13% ; 10% at our institution). Although these rates likely exceed the total risk, it isn’t clear how they can be further reduced. That certain centers report far higher rates of surgery [141, 148, 149, 150] likely reflects referral biases and/or overly aggressive intervention. Major complications of decompressive surgery are rare  and the quality of life of those undergoing decompression is not compromised long term .
If, as suggested, such intervention is lifesaving, then with universal assessment and intervention 4–5 lives per year should be spared in the United States, and around 100 per year worldwide. As noted, there is evidence that routine assessment and intervention as outlined does decrease mortality in infants with achondropasia .
Special concerns in the young infant: restrictive pulmonary disease
Infants with achondroplasia often have small chests . In addition, there is increased compliance of the rib cage, sometimes dramatically so. That excess compliance is manifest as paradoxical movement with inspiration in most young infants with achondroplasia – sinking inward principally of the inferolateral part of the chest, but also often substernally. Mild deformity of the chest may also be present , including lateral indentations and pectus excavatum. The combination of these features – small chest, presumably but not certainly reflecting smaller anatomic lung volumes, inefficient chest mechanics, and chest deformity – together may result in smaller effective lung volumes.
Despite these features, most babies suffer no evident consequences. Predictably it does result in more rapid desaturations with physiologic sloppiness of central respiratory control or with minor obstructive events, making interpretation of polysomnography more challenging in young infants. Small chest volume also causes diaphragmatic descent and “pseudo-organomegaly” (with a liver edge often palpable well below the inferior costal margin).
In a small proportion this set of features can result in chronic hypoxemia. This is particularly likely in those living at high altitude (personal observations). Chronic hypoxemia can be of sufficient severity to result in failure to thrive (presumably because of increased work of breathing), rarely respiratory failure, and, potentially, cor pulmonale if not addressed [118, 152, 153].
Assessment is straightforward. Clinically persistent marked tachypnea, secondary feeding difficulties because of that tachypnea, additional signs of chronic respiratory distress and failure to thrive may be present. In all babies with achondroplasia polysomnography needs to be completed for other indications (see above). This also will provide a long oximetry sample. Saturation dips into the high 80s are normal in infants with achondroplasia (personal observation). Low baseline oxygen saturation and/or frequent desaturations unaccompanied by recordable respiratory events will likely reflect restrictive pulmonary disease. In addition, daytime spot oximetries, both during active alert time and, particularly, during feedings for example, may be helpful. Chest circumference measures compared with achondroplasia standards may also be of some help .
In those with restrictive pulmonary disease, the help of a pediatric pulmonologist should be sought. Oxygen supplementation alone may be sufficient to maintain saturations and reverse failure to thrive. If not, tracheostomy may be needed. Restrictive pulmonary disease has been the principle condition resulting in need for tracheostomy in a small subset of babies with achondroplasia: At our institution ~ 1–2% of babies have required tracheostomy, primarily to eliminate dead space in those with restrictive disease. In all, it has been temporary.
Given that the activating mutation of FGFR3 that results in achondroplasia causes a general inhibition of endochondral bone growth, of course one would anticipate that all of the long bones of the body will grow slowly; and they do. Small stature is the signal characteristic of achondroplasia.
Although length at birth may be normal [61, 154], slow growth is evident shortly thereafter. Moderate to marked short stature is present in all affected individuals. In adult males average height is about 130 cm (4′3″) with a range from around 120 to 145 cm. Similarly, in females average height is 125 cm (4′1″) with a range of 115 to 137 cm. Average adult heights are about − 6 to − 7 S.D. below the mean for average stature individuals .
The achondroplasia mutation modifies rather than negates other genetic determinants of growth . Height variability in individuals with achondroplasia seems to correlate just as strongly with parental heights as it is in average individuals. That is, tall parents will tend to have tall achondroplastic offspring and short parents, shorter than average achondroplastic children.
Small stature has substantial consequences for the affected individual. There may be psychological sequelae, which possibility needs to be addressed with parents and the affected individual. Physical limitations result, as well, and there will be need for environmental adaptations, particularly in school (see below). Note, however, that sitting height is near normal . This is of relevance with respect to, for example, safe transitions from carseat to booster and regarding adaptive needs for driving.
Possible treatment of small stature
To date no treatment has been devised that will negate the effects on growth of achondroplasia (but see also Possible future therapies below). A substantial number of studies have been published regarding the use of growth hormone therapy to enhance growth in children with achondroplasia (for example [162, 163, 164]). A transient increase in growth velocity is predictably found, but the effect diminishes with length of treatment. Of the many published studies, virtually none has followed treated children to the completion of their growth . However, Harada et al. recently described an uncontrolled observational study in which the final heights of achondroplasia patients who were treated with recombinant growth hormone were assessed. Following long-term therapy, average increase in adult height was + 2.8 cm in females and + 3.5 cm in males . So, one can anticipate around 1 to 1 ½ inches of additional adult height following years of injections. Most families recognize the disadvantages of both daily injections and the accompanying medicalization of small stature, and few elect to pursue growth hormone therapy.
Extended limb lengthening is offered as another option for height enhancement [167, 168, 169, 170]. A variety of techniques have been used, generally through osteotomies and gradual distraction using external fixators. Substantial lengthening and height enhancement can be achieved, so that potentially one can achieve an increase in adult height of 25 cm or more. This is a long and arduous process. High complication rates can be expected . It has been used in many patients with achondroplasia; most of these lived outside of the United States, perhaps because of different attitudes toward outwardly evident physical differences. Most care providers and ethicists in this country have advocated that such surgery be postponed until the affected individual can participate in decision making (that is, in preadolescence or later), and that it should only be completed in a center offering comprehensive, multidisciplinary care .
Early in life feeding difficulties may arise because of tachypnea, gastroesophageal reflux, oromotor hypotonia or some combination of these. Together with increased work of breathing (see above), failure to thrive may result. Thereafter, however, obesity is prevalent, probably far more prevalent than in the population at large . Excess weight may be particularly problematic in persons with achondroplasia related to potential neurologic and orthopedic sequelae .
All currently available ponderal standards are population based – they reflect what is, not necessarily what should be.
Interventions for obesity
Energy expenditure and caloric need appear to be less in those with achondroplasia . Although typical interventions to prevent or treat excess weight are usually effective, this means that efforts at weight loss may need to be more rigorous and aggressively supported. Experience suggests that, in general, caloric need in those with achondroplasia is about 2/3 that of individuals with average stature.
Bariatric surgical procedures have been successfully carried out in obese adults with achondroplasia  (and personal observations).
Cognitive function is normal in most persons with achondroplasia [179, 180], although it has long been recognized that developmental delays, particularly motor delays, are common [179, 181]. Of course, cognitive issues may arise secondary to other sequelae of achondroplasia – hydrocephalus, hypoxic injury and so forth. Furthermore, untreated obstructive sleep apnea may have serious developmental consequences in children with achondroplasia .
The first attempt to provide standards for comparison of development in a child with achondroplasia to similarly affected peers was that of Todorov et al.  The resultant tool, patterned after the Denver Developmental Screening Test , served only as a very rough guide to expected development; this is particularly so because it was generated using temporally remote retrospective recall. Furthermore, it addressed possible delays in development but not differences in development.
Gross motor delays are substantial. Median age of walking independently is around 18  or 19  months. Those medians hide a remarkably broad range, so that first independent walking may not occur until well after the 2nd birthday . Gross motor issues may be sufficient that with increasing age they result in greater caregiver dependence .
A larger than expected number of children with achondroplasia have language delays [188, 189]. Documented delays are most often of expressive language [9, 190]. Unrecognized persistent or fluctuating hearing loss is common in those with achondroplasia (see Ears and hearing), and may explain much of these expressive delays . It also may, in part, arise from how adults interact with children with achondroplasia . It may in part be related to the expression of FGFR3 in the brain . In the vast majority of children with such expressive language delays, with appropriate speech and language therapy normalization will occur by 5 or 6 years of age (personal observation).
It appears that quite infrequently, but still at a higher frequency than in the general population, children with achondroplasia may have autism spectrum disorders . This possibility has not yet been adequately documented or confirmed.
Neurologic risks: hydrocephalus
Most individuals with achondroplasia are macrocephalic . Large head size appears to have multiple contributing factors. Megalencephaly of mild degree is typical , perhaps because of direct effects of FGFR3 on brain morphogenesis ; typically there is both ventriculomegaly and excess extra-axial fluid , presumably a result of a mechanism shared with the process that sometimes results in hydrocephalus  – see below. It is critical to distinguish between “normal” macrocephaly with large ventricles under normal pressure and excess extra-axial fluid, and clinically significant hydrocephalus.
Level of risk
Although Hunter et al. reported that ~ 10% of individuals in a multicenter review had a ventricular shunt placed , because this retrospective assessment covered many decades, it is likely this includes persons in the earlier part of the period who were shunted without what would now be considered unequivocal need. A more recent study reported an incidence of 4.3% of children with achondroplasia requiring shunting . This is more in keeping with our own experience. Diagnosing those 3–5% of children who require treatment is challenging.
In a few children it appears that there is intermittent, episodic increased intracranial pressure [25, 197, 198]. This may result in acute and severe symptoms, but without persistence. Whether this is present and relevant can only be assessed with intracranial pressure monitoring .
Rarely infants will have acute and dramatic signs and symptoms of hydrocephalus. More often, its development is more insidious, with mild and difficult to pinpoint symptoms such as lethargy, irritability, headache etc. In those instances signs become more important. Parents should be taught that a bulging and tense anterior fontanel, or increasing prominence of superficial venous patterning (see below), along with lethargy or irritability and/or emesis requires urgent assessment.
Although this is likely the most important mechanism, there is also evidence that obliteration of cerebrospinal fluid flow at the craniocervical junction may be a factor in development of hydrocephalus, too [128, 129, 201, 202]. It is not unreasonable to posit that there are two distinct processes that can give rise to increased intracranial pressure in those with achondroplasia.
One might think that jugular foramenotomy would be the logical approach, and this has been successfully done . However, this is challenging surgery and has not supplanted use of ventriculoperitoneal shunting.
Third ventriculostomy has been carried out in a few children with achondroplasia, apparently successfully [196, 204]. Good outcomes with this procedure (which should not be effective if intracranial venous hypertension rather than obstruction is the mechanism of hydrocephalus) could mean either that intervention was not really needed, or that a second, obstructive mechanism such as flow restriction at the craniocervical junction may sometimes be important .
If there are, in fact, two distinct mechanisms giving rise to hydrocephalus in those with achondroplasia, distinguishing which mechanism or mechanisms is operative in an individual is not straightforward.
Distinguishing which intervention is most effective is, in theory, uncomplicated. Prospective randomization to two alternative treatment arms of patients presenting with signs and symptoms of hydrocephalus is easy to envisage. However, in practice such a trial is virtually impossible. Over the course of 30 years, the largest specialty clinics assess around 400 unique individuals with achondroplasia . Each such clinic, then, would identify only around 0.7 eligible patients ([400 ÷ 30] × .05) per year. Not only would a collaborative venture be needed, but even so only after many years would sufficient numbers be accumulated.
The subarachnoid spaces are enlarged in most children with achondroplasia. Because of this increased extra-axial fluid, the bridging vessels (which may also be distended because of obstruction at the jugular foramina) may be especially susceptible to shearing trauma. Several instances of subdural hematoma formation in children with achondroplasia  (and personal observation) following minimal trauma probably arose because of this increased susceptibility. Such an occurrence should not be interpreted as necessarily implying that nonaccidental trauma has occurred.
Neurologic risks: the craniocervical junction after infancy
Although the risk for unexpected death secondary to craniocervical constriction nearly disappears after the first year of so of life [8, 107, 113], the foramen magnum remains small. This results in a residual risk that an individual may experience spinal cord damage, either insidiously or acutely. That high cervical myelopathy develops in some individuals with achondroplasia has been recognized for a long time [115, 206, 207]. Such cervical myelopathy can arise at any age , although it seems more frequent in childhood – perhaps because of continued, albeit slow, growth of the chondrocranium with age  or perhaps because precipitant trauma is more likely in children. No estimate is available for level of risk.
In young children clinical features that may suggest cervical myelopathy include long persisting hypotonia, asymmetric resistance and strength, asymmetric reflexes, ankle clonus, or upgoing response to Babinski stimulation . After a child begins to ambulate, note may be made of classic features of cervical myelopathy  including orthograde fatigability, decreased endurance, apparent sudden, transient pain in the arms or legs, decreased fine motor function or changes in bowel or bladder continence. Alternatively, a child may present with acute, severe myelopathy secondary to injury  which requires urgent neurosurgical involvement.
Given risks related to craniocervical constriction, all individuals with achondroplasia must be managed as having a small foramen magnum and increased risk for trauma-based cord compression. It is crucial that parents be counseled about physical activities and sports activities that create unacceptable risk [1, 4]. Activities that should be prohibited, or at least strongly discouraged, include: trampoline use; vaulting in gymnastics; diving off of diving boards; sparring in martial arts; (American) football; rugby; downhill skiing; heading in soccer, etc. On the other hand, many physical activities are reasonably safe and can be encouraged, such as: swimming; golf; tennis; basketball; soccer (except for heading and only at younger ages, since competitive soccer becomes much more risky in older children); baseball; softball. If parents understand that what one is trying to do is limit activities that cause substantial risk for forceful head and neck injury, they usually can assess whether a particular endeavor is unsafe. Note that because what creates risk is violent neck movement, helmet use is not preventative.
In younger children, continuing rear facing of the car seat for as long as tolerated is probably prudent. Safety precautions such as gated stairways are also especially important.
Some healthy and asymptomatic children when examined carefully have “leftovers” of presumed temporally distant and minor cervical cord injury, including for example, ankle clonus, upgoing response to Babinski stimulation, etc. (personal observation). The only relevance of these findings probably is to document in medical records and to explain to the parents their presence, since they may be cause for undue concern in some circumstances. There are reports of MRI T-2 signal abnormality at the craniocervical junction in as many as 40% of apparently asymptomatic adults with achondroplasia [140, 210, 211]. These were often associated with thinning of the cord in the same region . Although the origin of these lesions is unknown, it is conceivable that they reflect gliosis arising secondary to such temporally distant, minor cord injury , which injury could be either direct compression or of vascular compressive origin. Because careful neurologic examinations are not reported, postulating a relationship between these lesions and the clinically demonstrable “leftovers” remains speculative, however attractive.
In contrast with some other bone dysplasias, atlanto-axial instability is exceedingly rare in achondroplasia with only a handful of cases reported in the literature [212, 213]. It is so infrequently a concern that it probably does not need to be evaluated in any routine circumstance.
Neurologic risks: miscellaneous
Although far more common in those with hypochondroplasia , seizures occasionally arise in those with achondroplasia [214, 215]. In fact, paroxysmal events with apnea in infants with achondroplasia may arise from a variety of causes: secondary to abnormalities at the craniocervical junction and consequent abnormality of central respiratory control; from primary seizures; from airway obstruction related to macrocephaly and hypotonia (e.g. when in a car seat); or from gastroesophageal reflux. Particularly in infancy, distinguishing primary apnea from seizure-precipitated apneic events may be challenging.
Temporal lobe abnormality
Temporal lobe dysgenesis is common in individuals with hypochondroplasia secondary to FGFR3 mutations [83, 84]. Given that achondroplasia and hypochondroplasia belong to the same family of bone dysplasias , it would not be surprising to identify similar dysgenesis in occasional individuals with achondroplasia. In fact, that was recently reported by Manikkam et al.  In neither disorder has the frequency of temporal lobe structural abnormalities been determined. Nor has the frequency with which temporal lobe dysgenesis results in seizures, or whether temporal lobe abnormalities are a marker for more severe central nervous system consequences of FGFR3 been determined.
Both central apnea and restrictive breathing problems, which for the most part are exclusively issues in young infants, have already been addressed. In addition, children and adults with achondroplasia have an exceedingly high frequency of obstructive sleep apnea [153, 216, 217].
Estimating the frequency with which people with achondroplasia have sleep apnea is challenging. Ranges (in all age groups) have been from 10 to 87% [217, 218]. Most series suffer from inadequate sample size and/or ascertainment and referral biases . Nonetheless, in published sequential series, most find that obstructive apnea of clinical significance arises in around 1/3 of all individuals (combining all ages) with achondroplasia (e.g., 38% in Sisk et al. ; 34% in Afsharpaiman et al. ; 32% in Collins & Choi ).
Obstructive sleep apnea may present at any age. In fact, there is a remarkably high rate of obstruction even in children less than 2 years of age . Not surprisingly, however, there is a dramatic increase as physiologic hypertrophy of the lymphatic ring – and particularly the adenoids – arises between around 2 and 10 years of age.
Screening for possible obstructive apnea is challenging . Nonetheless, either a parent (in children) or a sleep partner (in adults) should be taught the features that suggest that clinically significant increased upper airway resistance is present. In children with achondroplasia, soft and regular snoring occurs in around 95%, and so is not a valuable marker; this probably simply reflects air turbulence associated with anatomically small airways. Likewise, most infants with achondroplasia perspire profusely and this is not indicative of any medical issue. Features of significance in children include: neck hyperextension; loud and irregular snoring; glottal stops; observed apnea; deep, compensatory sighs; self-arousals; secondary enuresis; night-time emesis; morning headaches  (and personal observations). Of these, Sisk et al.  noted that glottal stops and observed apnea were the most predictive of finding clinically significant abnormalities by polysomnography. Daytime features in the very young are difficult to discern, but may include increasing sleep duration per 24 h period. In older children, there may be change in school performance or changes in behavior, including new onset of distractibility and poor attention .
In adults, there are daytime behavioral scales that can be used to query about symptomatic apnea . Results using such a scale along with the sleep partner’s description of breathing pattern in sleep can help guide whether polysomnography should be done.
Consequences of untreated obstructive apnea
Parents need to be assured that obstructive apnea is almost never an acutely life threatening problem, but rather has long term effects that must be mitigated. Consequences of sleep apnea are not markedly different in individuals with achondroplasia compared with the general population. As mentioned, in children there may be negative learning and behavioral consequences [221, 223]. Because pulses of growth hormone secretion occur during sleep , sleep disruption can negatively affect growth, independent of the primary diagnosis of achondroplasia.
In adults daytime symptoms arising from poor sleep quality at night markedly increase the risk of various kinds of accidents .
Physiologic consequences can arise at any age. Particularly concerning are the cardiovascular consequences of long term sleep apnea , which are observable in affected individuals with achondroplasia . Not only may obstruction resulting in recurrent and prolonged desaturations result in pulmonary hypertension and eventual cor pulmonale, but it may be a critical contributor to hypertension risk .
In children, a number of factors conspire to make obstructive apnea far more likely. In everyone there is physiologic decreased muscular tone in sleep  resulting, effectively, in smaller airway size. In children with achondroplasia there is hypoplasia of the midface with consequent diminution of anatomical airway size [152, 229, 230]. The anatomy of the face is predictive of likelihood of obstructive apnea in average children  and in children with achondroplasia, too  – the flatter and retruded the midface, the more likely that sleep apnea may develop. After around age 2 years there is physiologic hypertrophy of the lymphatic ring . These factors are likely the major contributors to pathogenesis of obstructive apnea in most children with achondroplasia.
Other factors may play a role in some. Centrally mediated obstruction (as well as decreased respiratory effort) may arise because of cranial base abnormality [119, 142]. Gastroesophageal reflux is sometimes a critical contributor . Lower airway malacia (tracheobronchomalacia) has recently been recognized to be of substantial frequency in achondroplasia and does complicate the management of other factors resulting in obstruction .
In adults, midfacial abnormality persists, while lymphatic obstruction is usually not significant. The most critical additional factor in many adolescents and adults is the onset of obesity, a feature strongly related to sleep apnea .
The first steps in assessment is to elicit observational history regarding all of the features discussed above under Clinical presentation. General clinical assessment should include evaluation of severity of midface hypoplasia, degree of tonsillar hypertrophy and evidence for nares patency. In addition, contributing factors not unique to achondroplasia such as allergic rhinitis need to be ruled out.
If concern is present, two approaches can be considered. Polysomnography will objectively document the presence of and severity of obstructive apnea and disordered breathing, and is often the first elected investigation [4, 218, 219]. In children with severe and unequivocal historical symptoms, alternatively one might choose to have otolaryngologic evaluation including nasopharyngoscopy  completed. The latter approach, however, while allowing more rapid initiation of intervention if needed, does not provide objective data against which post-treatment studies can be compared.
When serious obstructive abnormalities are demonstrated by polysomnography, then referral should be made to a pediatric otolaryngologist for evaluation.
Stepwise management of obstruction in children typically begins with adenoidectomy with or without tonsillectomy. Although one would expect that adenoidectomy along would usually suffice, outcome appears to be better in those who undergo tonsillectomy as well . Children with achondroplasia may have an increased risk for post-operative complications  and probably should be hospitalized overnight following any procedure requiring intubation. While a majority will show marked improvement after surgical intervention  nevertheless polysomnography should be completed a few weeks after surgical intervention, since in many individuals obstruction persists at a level requiring additional treatment . In those in whom additional treatment is needed, step two is the use of positive airway pressure (cpap, bipap). Positive airway pressure treatment is effective in those with achondroplasia [219, 229], including in very young children (personal observation). In a large majority, those interventions are sufficient to correct the obstructive apnea and prevent sequelae.
Rarely additional treatment may be needed. Uvulopharyngopalatoplasty  has occasionally been done, but the numbers are so small that benefit is difficult to assess. Rare individuals may require temporary tracheostomy (personal observation), although this is more likely to be needed for restrictive disease in infancy than because of inability to otherwise treat obstructive apnea. Occasionally surgery has been done to correct the midfacial hypoplasia, when severe, by either midface advancement  or distraction [239, 240].
In adults, most often positive airway pressure treatment is the primary and most important intervention. If appropriate, it needs to be accompanied by efforts at weight loss. The role of surgery in adults with obstructive apnea is unclear.
Ears and hearing
Middle ear dysfunction is exceedingly common in both children and adults with achondroplasia. This presumably is so because of poor functioning of abnormally oriented Eustachian tubes, which abnormality, in turn, arises because of aberrant growth of the chondrocranium .
A number of studies have assessed middle ear function and hearing in achondroplasia. All are limited, because of sample size (e.g. Glass et al. ; Shohat et al. ; Collins et al. ), ascertainment bias (e.g. Glass et al. ; Collins et al. ), incomplete documentation (e.g. Hunter et al. ), or self-referral bias (e.g. Tunkel et al. ). A well-designed, prospective study is very much needed. Nonetheless, currently available information provides a reasonably clear picture of middle ear issue5s in achondroplasia.
Middle ear dysfunction arises in 50–70% of individuals with achondroplasia [141, 242]. In turn, this results in approximately 50% of individuals having pressure equalizing tubes placed at some point [4, 141, 245].
Estimates of the frequency of hearing loss range from 38 to 60% in the achondroplastic population overall [195, 242, 244, 246]. In a large, cross-sectional study of a convenience sample, Tunkel et al.  demonstrated that 40% of the tested population failed hearing screening (even with relaxed criteria). This issue is not solely one of childhood , although greatest concern is appropriately centered on the period of language acquisition in early childhood, during which hearing loss can be a major factor contributing to speech and language delays.
Assessment and management
A high level of suspicion of possible hearing loss is appropriate at all ages. Formal behavioral hearing assessment and tympanometry should be completed by around 1 year of age . These should be repeated at least yearly at least until school age [1, 244].
Because medical management of middle ear dysfunction is usually ineffectual , pressure equalizing tube placement is usually appropriate. Once need is demonstrated, tubes will usually be needed at least until 7–8 years of age .
There is an increase in the occurrence of jugular bulb dehiscence into the middle ear space [247, 248] (again because of abnormality of the chondrocranium). This can sometimes causes persistent, unilateral hearing loss . Occasionally is can cause unexpected, brisk bleeding from myringotomy if not recognized before surgery .
When hearing loss is documented in childhood, standard approaches to habilitation are appropriate. These include parental awareness, preferential seating in school, use of environmental amplification if needed, etc. In only a few children are hearing aids warranted. However, note should be made of the remarkably high frequency of hearing loss in adults and, as well, the remarkably low frequency of hearing aid use in them . It is likely that many adults would benefit from amplification.
Orthopedic concerns: kyphosis
That progression arises from deleterious effects of gravity acting at a disadvantageous angle because of positioning of the infant was first suggested by Beighton and Bathfield . We suggested that a biophysical explanation of progression was likely secondary to a number of nearly uniform features in infants with achondroplasia: hypotonia; macrocephaly; generalized ligamentous laxity. These features mean that when placed in a sitting position, a slumped, C-sitting posture will arise, which can lead to anomalous gravitational forces causing remodeling of an intrinsically abnormal spine .
In those individuals who were not counseled regarding preventive strategies, or in whom prevention and bracing fails, surgery is appropriate [252, 254, 261]. The aims of surgery are to reduce the severity of the curve, decompress the spine and stabilize it . Spinal arthrodesis with instrumentation seems to be the most effective approach , although, of course nothing approaching a controlled study regarding alternative options has been published. Generally surgery is undertaken at around 10–12 years of age [252, 261] in order that late growth not precipitate worsening neurologic status, although some have advocated initial surgical intervention far earlier in life .
Orthopedic concerns: lordosis
Hyperlordosis is usually asymptomatic and requires no treatment. When marked, there may be an increased incidence of pain at the apex of the curve. When marked, it may also increase the likelihood for intermittent spinal claudication or symptomatic spinal stenosis in adolescents and adults (see below) [263, 264]. Because it may result in a fully horizontal sacrum (Fig. 38), an occasional child may develop pressure-induced, chronic coccydynia (which can be managed with padding of underwear [personal observation]).
Severe hyperlordosis may be diminished in severity by a physical therapeutic exercise program – low back and lower abdominal muscle strengthening and pelvic rotations (personal observation). Because cooperation and compliance are unlikely in young children, generally physical therapy is not appropriate before 5–7 years of age.
Orthopedic concerns: lumbosacral spine
All individuals with achondroplasia have substantially diminished caliber of the spinal canal along its entire length [265, 266]. A combination of factors contribute to this and to foraminal narrowing. The spine shows decreased interpediculate distances, short and thick pedicles, and many affected individuals have some degree of thoracic kyphosis and lumbar hyperlordosis. The latter two features may make symptomatic spinal stenosis more likely .
For the most part, issues arising from the anatomic lumbosacral stenosis are problems of late adolescence and adulthood, with average age of symptoms onset in the 4th decade [256, 268]. The proportion of individuals experiencing symptoms rises from about 20% by age 20 to 80% in the 6th decade . Likely, this is because with age secondary problems, such as arthritis, disk disease, etc. that arise in the general population, similarly arise in those with achondroplasia [263, 264]. Earliest symptoms typically are back pain and buttock pain, with gradual distalward progression of discomfort [195, 269].
It is important to distinguish between intermittent spinal claudication  and potentially irreversible symptomatic spinal stenosis, a distinction that is often not made in the surgical literature.
Intermittent spinal claudication
Exercise induced intermittent spinal claudication (neurogenic claudication) is a disorder of the elderly in the general population . In contrast, it commonly arises in older children and young adults in those with achondroplasia.
Critical in its differentiation from bony compressive changes in the spine, claudication arises with orthograde activities and resolves (often quite quickly) with rest. Symptoms may include exercise induced tingling, numbness, pins and needles, pain, or a heavy feeling in the legs. Stopping the precipitating activity (standing, walking, running) results in resolution in seconds or minutes. Often persons with achondroplasia find that more rapid relief arises with squatting (personal observation). With careful questioning, a majority of adults report some of these features, but many seek assessment only if walking limitations become marked.
Neurogenic claudication probably arises because of vascular congestion that is increased by blood flow changes associated with exercise and which results in transient nerve root ischemia . As such a mechanism implies, neurogenic claudication results in no permanent damage to the cord or nerve roots. Therefore it generally can be treated non-operatively. No studies have adequately assessed non-operative treatments in the general population , and their effectiveness in those with achondroplasia is utterly unexamined. Things seemingly of benefit include weight loss in the overweight and obese, low back physical therapy, and efforts to decrease the severity of hyperlordosis through an exercise program. Because no harm will accrue from physical activity, patients should be encouraged to continue to walk and otherwise exercise. Only if spinal claudication causes marked compromise of physical ability and of quality of life should surgery be considered.
Lumbosacral spinal stenosis
A smaller proportion of individuals develop more serious symptoms for which surgical intervention should be more often considered. Bony compression can be of nerve roots or the cord and cauda equina. Signs and symptoms that do not abate with rest suggest that problematic stenosis is developing. Features of particular importance include persistent leg weakness, clumsiness, changes in gait, and development of bladder or bowel incontinence . Clinical examination may demonstrate overt neurologic abnormalities at rest (which are not seen with intermittent spinal claudication), including asymmetries of strength, weakness, abnormal reflexes and/or sensory changes in the legs .
Such symptoms and signs should precipitate neuroimaging. However, every person with achondroplasia will have spinal stenosis , and that in itself should not be seen as justification for surgical intervention. Furthermore, imaging is remarkably insensitive and nonspecific in assessing spinal stenosis . What imaging can do is identify what levels are most severely anatomically affected, and what additional factors likely precipitated the clinical deterioration. Such documentation is critical when surgery is considered.
Generally, surgical treatment involves extensive and wide posterior laminectomy [254, 264]. Given that virtually all studies regarding operative intervention are retrospective and are subject to ascertainment biases, recall biases, incomplete follow-up and so forth, all conclusions about surgery remain subject to debate and will continue to be so until (and if) prospective, controlled studies are carried out. Tentative conclusions include the following. While lumbosacral spinal stenosis may occasionally require surgery in childhood [267, 268], more often surgery is carried out in the 4th and 5th decades [195, 268]. How quickly after onset of symptoms surgery should be done (versus a trial of non-operative interventions including physical therapy ) is controversial , with some data supporting aggressive operative intervention soon after onset of symptoms . Improvements following laminectomy do generally arise . As in the general population , there is less apparent benefit with time post-surgery, with Pyeritz et al. reporting for example that only ½ of treated individuals show long term benefit .
Orthopedic concerns: knees and lower legs
As in the wrists and hips, most children with achondroplasia have excess mobility of the knees. Usually young children show both genu recurvatum (hyperextension beyond 180°) and mediolateral instability. Recurvatum is often between 20° and 70°, apparently secondary to abnormality of form of the tibial plateau [273, 274]. Although this feature is usually insufficient to cause major symptoms or require surgery , rarely there is overt tibiofemoral subluxability (personal observation), which is one of the few circumstances in which transient bracing of the knee in a child with achondroplasia may be appropriate. Mediolateral instability is nearly uniformly present in young children with achondroplasia. This often seems to contribute to focal pain precipitated by orthograde physical activity (personal observation). Usually it lessens with age, disappears by adulthood, and rarely, in itself, requires any intervention other than non-specific treatments for pain (rest, warmth, massage and nonsteroidal anti-inflammatories). Lateral instability may be an integral part of the bowing deformity that is often present in those with achondroplasia, both contributing to this problem and responding to its treatment.
Bowing of the legs is a normal feature of average statured children in the first 2 years of life . In average children, early bowing presumably arises secondary to intrauterine positional effects , becomes apparent with first walking but then transitions to overcorrected valgus deformity by around 3 or 4 years of age [275, 276].
This is in contrast to what is seen in achondroplasia. In the child with achondroplasia there is often inexorable, continued progression of varus deformity. Between 1/3 and ½ of all children with achondroplasia have substantial bowing at the knees and of the lower legs [273, 277, 278]. Around ¼ will require surgical intervention related to symptomatic bow leg deformity [195, 273]. The severity of bowing is often asymmetric [279, 280]. There is some suggestion that males may be more often affected with clinically relevant bowing than are females .
Although referred to as ‘bowing’, in fact the knee and lower leg deformity is not an abnormality within a single, lateral plane. Rather, there is usually lateral, dynamic instability of the knee, varus of the tibia, internal tibial torsion and tibia recurvatum . The complexity of the dynamic deformity is well illustrated using gait analysis .
A major concern in average statured individuals is that substantial varus deformity (of 15° or more) predisposes to knee osteoarthritis . In contrast, arthritis does not seem to be common in adults with achondroplasia , although no substantive study has been done to confirm this.
Symptoms that arise most frequently include activity-precipitated pain and self-limitation of walking and other orthograde physical activities .
Clinical assessment should include asking about activity induced discomfort or pain. Often children will report pain particularly after physically busy days with onset in the afternoon, evening or awakening them from sleep.
Severity of genu recurvatum and of mediolateral instability of the knees;
Measurements of distances between the knees, mid-tibiae and medial malleoli (Fig. 39) (with serial assessment to identify progression and its rapidity through serial clinical measures without the need for frequent radiographs);
Measurement of thigh-foot angle (Fig. 39) to assess the severity of internal tibial torsion;
Evaluating whether the weight bearing joints remain ‘in plumb’ in a standing position (Fig. 39), which is helpful in deciding if orthopedic surgical assessment is warranted – in those who are out of plumb, such assessment is indicated ;
Evaluation of gait, particularly to ascertain if there is sufficient lateral knee instability to cause a “thrust” – sudden outward movement of the knee with weight bearing.
In addition, in those in whom there is concern about the severity of bowing or who have serious symptoms referable to bowing, radiographic evaluation should be done. Most helpful is a standing, full leg length image with the patellae pointing forward (irrespective of the resultant foot position) .
Mechanism of development
There is no consensus about the relative importance of a number of factors that may contribute to the complex varus deformity of achondroplasia. That is unfortunate, since strategies for intervention are at least in part predicated on assumptions about mechanism.
Bowing probably is two discrete processes. In young children the varus deformity is usually primarily proximal – just distal to the knee, while in adolescents varus tends to develop just above the ankle . In young children factors that have been suggested as being important include fibular overgrowth , lax lateral collateral ligaments [288, 289], as well as true deformity of the tibia. The relative contribution of each of these and how they interact  has yielded conflicting evidence. For example, while Ain et al.  found no relationship between fibular overgrowth and severity of bowing, Lee et al.  showed just the opposite. Absent clear association, and most certainly absent any evidence that fibular overgrowth is actually a primary cause of leg bowing, there is little to suggest that primary surgery on the fibula is likely to be effective.
In those in whom any of the following features are present, surgery should be considered: three weight bearing joints out of plumb; persistent lateral knee pain not relieved by conservative measures; development of a lateral thrust . Standard surgery is a valgus producing and derotational osteotomy of the proximal tibia as well as some method to shorten the fibula in order to effectively tighten the lax lateral collateral ligament [286, 289]. Obviously, intervention is tailored to the evaluative findings in a particular child; some may require multi-level osteotomies; in some older children distal tibial osteotomy is appropriate . All such surgery has risk for substantial complications such as infection, malunion, compartment syndrome, peroneal palsy, and need for additional surgery because of recurrence .
Alternatives have been suggested in the past but not enthusiastically embraced currently. It was suggested that proximal fibular epiphyseodesis could be a simple surgical way to prevent development of bowing . Of course this assumes that fibular overgrowth is the primary pathogenetic precipitant of bowing. Partial fibulectomy (alone) has also been considered . This would, presumably, both decrease the tension of the fibula and tighten the lateral collateral ligament. There seems to be no literature suggesting that direct operative treatment of the lax lateral collateral ligament is a reasonable option.
Guided growth (or “growth modulation”) using ‘8-plates’ is a means of effecting gradual correction of angular deformity by temporarily limiting growth on one side of a growth plate [291, 292]. Its role in treating varus deformity in achondroplasia is currently unsettled. On the surface, use of 8-plates appears to be illogical since one might expect that they would only correct one dimension of the complex deformity that it usually present. In addition, questions remain whether a ‘sick growth plate’ will respond similarly to that in children of average stature . Certainly, given the slow rate of growth in bone dysplasias, correction will be far slower and symptoms will not be relieved for the time needed for correction. Nonetheless, impressive outcomes have been demonstrated (P. Stevens, personal communication 2015). Limited published data regarding its use in those with achondroplasia  suggest that at least partial correction of malalignment can be accomplished. There even is anecdotal evidence that correction in one plane (varus deformity) will secondarily results in improvement of the other components (internal torsion and lateral instability) (P. Stevens, personal communication 2015). Whether this (surgically far simpler and far less debilitating) option is a good alternative remains uncertain.
What is the pathogenetic mechanism giving rise to varus deformity?
How much genu varum is tolerable in those with achondroplasia?
What is the prevalence of knee osteoarthritis in adults with achondroplasia, and does it correlate with the severity of varus deformity? Recent animal studies suggest that activation of FGFR3 may confer protection against development of osteoarthritis [295, 296]. If this is true in humans as well, then those with achondroplasia may tolerate more severe bowing without debilitating secondary arthritis than is the case in the general population.
What are rational indicators for surgery?
At what age is surgery best undertaken?
What should be the role of 8-plates in treating bowing?
Other features of the knees in those with achondroplasia
The availability of imaging techniques – particularly magnetic resonance imaging and direct visualization by arthroscopy – has resulted in recognition of a number of anatomic variants of the knee in achondroplasia [285, 297]. Of these, the finding likely of greatest significance is an exceedingly high prevalence of discoid lateral menisci.
Although relatively common in the general population , there seems to be a much higher prevalence in children and adolescents with achondroplasia who present with knee pain. There are a host of causes for knee pain in this population, the most common of which is varus deformity. A discoid lateral meniscus, which may predispose to meniscal injury [298, 299], should be considered particularly in those with lateral joint line pain and tenderness [285, 299, 300]. Unfortunately, to date the data related to discoid lateral meniscus suffer from the usual problems – small series, ascertainment biases, uncontrolled interventions, etc. However, that treatment of torn discoid lateral menisci does seem to result in symptom resolution suggests that this may, in fact, be another cause of knee pain in children and adolescents with achondroplasia.
Orthopedic concerns: shoulders, elbows and wrists
Shoulder hypermobility is virtually constant in individuals with achondroplasia  (and personal observation). This evidently arises because of unusual shape of the humeral head so that anteroinferior subluxability out of the glenoid fossa may occur, but, while subluxability is common, pain because of this instability is rare . Nonetheless it is probably prudent to limit the frequency of induced subluxation. Two activities (and likely others with similar dynamics) seem to particularly precipitate subluxation – butterfly stroke in swimming and dead-lifting of weights (personal observations). Therefore, in those with clinically demonstrably unstable shoulders (anteroinferior subluxability, apprehension sign) those activities should be avoided. Increasing subluxability has also been noted during humeral lengthening .
In contrast to nearly all other joints, the elbows are stiff in those with achondroplasia. Most individuals develop limitation of elbow extension beginning in childhood . Usually this is moderate, ranging from around 20° to 60° of decreased extension . This results in effective shortening of the arms even more, and limits reach accordingly. In the minority in whom radial head dislocation arises, even greater functional consequences will result, since not only will reach be diminished, but pronation and supination will also be limited (although this can in part be compensated for because of excess mobility at the wrists). Nevertheless, surgical treatment is almost never appropriate, unless humeral lengthening is elected because of reaching problems. Such reaching problems often can be addressed by using various adaptive devices (see section Adaptive needs), Nonetheless, humeral lengthening (as part of general extended limb lengthening or alone to treat issues related to reach limits and adaptive needs) has been carried out in a large number of individuals with achondroplasia . This may be necessary in order to assure independence for perineal hygiene, particularly in those who have limitation of trunk mobility (e.g. because of surgical spine fusion). About 6–12 cm of lengthening (2–5 in.) of lengthening can be expected [302, 303, 304]. Although modest, this may be sufficient to allow for greater independence for personal hygiene.
The wrists in almost all children and in some adults are hypermobile  (Fig. 26). Some of those with hypermobility demonstrate marked dorsoventral instability (personal observation), which seems to correlate with functional difficulties related to wrist stabilization. Excess wrist movement and the need to stabilize the wrist for fine motor tasks can cause a number of problems. Some children complain of fatigability after very short periods of writing; others have difficulty generating sufficient pressure to even make marks with a pencil. A number of options have proven to be beneficial (see below under Adaptive needs). Surgery is never appropriate.
Many children appear to benefit from preparatory orthodontia. Palatal expansion  is often used to increase the width of the maxilla and to improve the effects of subsequent traditional orthodontia.
Mortality studies not only have shown an increased risk for death in infancy, but also greater rates of death across all ages [107, 108]. Particularly noteworthy is evidence of substantially greater risk of death secondary to cardiovascular conditions. Indeed heart disease related deaths were reported as ten times expected in young adults and, overall, twice the anticipated rate compared with average statured individuals .
A number of factors could cause these differences. It could be that there is a primary effect of FGFR3 on cardiovascular function. More likely it may be related to other risk factors that occur at higher frequency in adults with achondroplasia. These could include decreased physical activity (because of the physical challenges inherent in achondroplasia), increased obesity  or higher than typical incidence of lifestyle related risks.
Unrecognized hypertension is probably particularly important. Well over ½ of adults with achondroplasia are pre-hypertensive or hypertensive (J. Hoover-Fong, personal communication 2014). That this is underappreciated particularly arises because of the difficulty in obtaining accurate measurements because of the large circumference but short length of the upper arm. Therefore, many individuals with achondroplasia do not have routine blood pressure assessment and almost certainly are undertreated. Specific blood pressure cuffs (e.g. GE Small Adult Long Soft-Cuf), and use of the forearm when needed (J. Hoover-Fong, personal communication, 2014) should make better monitoring of this issue possible.
Low frequency but non-coincidental processes
Acanthosis nigricans is an infrequent but not rare consequence of achondroplasia [313, 314, 315, 316]. It typically is demonstrable as thickened, velvety, excessively pigmented skin of the neck and, less frequently, of the axillae and inguinal region . It most often arises in late childhood or adolescence [315, 317]. In a retrospective assessment of nearly 500 consecutive individuals, acanthosis nigricans was diagnosed in about 10% of those with achondroplasia . Parents and care providers should be reassured, first, that this is not dirt and cannot be scrubbed away; secondly, that it typically remains clinically mild; and third, that it is a harmless accompaniment of achondroplasia. The latter is important since, in other circumstances acanthosis nigricans is a marker for insulin resistance and diabetes . In this setting it is not .
Acanthosis nigricans appears to arise as a direct result of constitutive activation of FGFR3 . It is present in varying severity and varying frequency in many other FGFR3 disorders, including hypochondroplasia [315, 320, 321, 322], thanatophoric dysplasia [86, 87], SADDAN syndrome , Crouzon syndrome with acanthosis nigricans [97, 323], and in isolation with little or no skeletal abnormality [99, 100, 101]. Note that in these last, descriptions there is inadequate radiologic and clinical detail to clearly rule out a diagnosis of hypochondroplasia.
Craniosynostosis is the primary phenotypic consequence of certain FGFR3 mutations, particularly in Muenke syndrome . It is also a prominent feature of Crouzon syndrome with acanthosis nigricans  and thanatophoric dysplasias . In these, and in achondroplasia, FGFR3 mutations cause abnormalities of ossification in membranous bone including premature sutural fusion . It is not especially surprising, then, that craniosynostosis infrequently accompanies achondroplasia [186, 326, 327, 328, 329, 330] (and personal observations).
In achondroplasia, when craniosynostosis is present it does not seem to be suture specific, with involvement of the metopic [326, 327, 328], coronal [326, 328, 330], sagittal , (and personal observation), lambdoidal [326, 328], (and personal observation), frontosphenoidal , (and personal observation) and squamosal [328, 330] sutures, etc. in varying combination.
In a retrospective review, 4 of 477 (0.8%) consecutively assessed individuals with achondroplasia had confirmed craniosynostosis (unpublished personal observations). So, while uncommon, nevertheless should any type of calvarial asymmetry or unusual head shape be apparent, particularly if it worsens over time, assessment for craniosynostosis should be undertaken. If needed, surgery may be complicated by the presence of prominent emissary veins  that arise, as described above, secondary to jugular venous outflow obstruction.
Because of the biophysical differences present in both children and adults with achondroplasia, many adaptive needs may be present at all ages. At least in North America, most families and affected individuals have embraced the idea that the environment should be modified for the individual rather than requiring the individual to be ‘modified’ to fit a standard environment. Given the number of potential adaptations and the varied requirements of different ages, a complete description of all of these is beyond the purview of this review. Many alternatives can be found through the Little People of America (https://www.lpaonline.org). Likewise, general governmental mandates regarding accessible environments and accomodations for differences won’t be discussed. Four examples of adaptations needed by some individuals with achondroplasia are given below.
In young school-age children, the combination of brachydactyly and hand and wrist joint hypermobility often make certain fine motor tasks difficult. In particular, many children find it difficult to print with a standard pencil – making marks barely perceptible, or being unable to stably hold the pencil. Alternatives that can be tried to solve that difficulty can include use of free-flowing pens or markers instead of pencils, providing ‘fatty’ grips for the child’s pencils, using a small wrist stabilizing brace when fine motor tasks are being undertaken, or early transitioning to keyboarding. Involvement of an occupational therapist will often be beneficial.
As a final example – driving. Persons with achondroplasia generally do not need major modifications of an automobile such as hand controls. Two issues do need to be addressed, however. First, leg shortness usually requires the use of pedal extenders, which are available from a number of sources and which can be straightforwardly applied and removed when an automobile is shared with an average stature driver. Secondly, arm shortening results in most individuals with achondroplasia sitting very near the steering wheel. This is an issue related to air bag deployment from the steering wheel. For anyone in whom measurement from the middle of the steering wheel to chin or chest is 12 in. (~ 30 cm) or less, the driver side air bag should be disabled, since its deployment can result in life threatening injury in those circumstances [1, 331].
Quality of life
The impact of a medical condition such as achondroplasia can be thought of in a number of ways. In a broad sense, “quality of life” reflects all consequences of a disorder that are not narrowly medical. It can be divided between physical consequences that impact life’s quality and the psychosocial effects of the disorder. Unfortunately many quality of life studies have combined various skeletal dysplasias, and in only some can the specific effects of achondroplasia be parsed from the presented data [332, 333, 334]. Very few studies that can be considered assessments, in one way or another, of quality of life have been published specifically regarding achondroplasia [335, 336, 337, 338, 339].
In the medical domain, certain findings of quality of life studies stand out. First, pain is commonly present in adults with achondroplasia. Indeed, nearly 2/3 of adults report chronic pain, a figure dramatically higher than in the general population . Secondly, pain is associated with compromised physical function; that includes limited walking endurance and loss of independence for activities of daily living . In fact, 10–15% of adults were dependent on others for activities of daily living such as bathing and toileting . Third, overall functional health status is impaired in adults with achondroplasia (but only surprisingly mildly so), with much of that apparent decline arising in the 4th and 5th decades of life, and much of that related to lumbosacral spine issues . Gollust et al. also showed that quality of life in the health domain is diminished .
Psychosocial consequences of small stature have been described for a long time. That shortness of any cause can result in social problems, decreased self-esteem and so forth has been proclaimed by many, but remains a controversial issue . For chondrodysplasias collectively, Hunter showed that there is both apparent increases in depression and diminished self-esteem [332, 333]. Gollust et al. documented that in those with achondroplasia, there is diminished income, less education and less successful employment, and that all non-health domains of quality of life – social/economic, psychosocial/spiritual, family – were negatively affected . Achondroplasia, indeed, “constrains life”, despite obvious resilience in most of those affected .
Nishimura & Hanaki assessed psychosocial adaptation and coping in children with achondroplasia . Remarkably, they demonstrated unimpaired self-concept and effective coping strategies despite encountering negative experiences related to their small stature. Similarly, Rohenkohl et al. found that overall quality of life in children and young adults with achondroplasa was nearly identical to that of normal controls . The contrast with other, primarily adult-based studies is striking. Does self-image and self-esteem change with age? Or does this reflect a more positive attitude about dwarfing conditions directed toward this younger cohort? (Note, however, that Rohenkohl et al.  and Witt et al.  seem to have demonstrated improvement of quality of life with increasing age up to adulthood, a finding apparently incompatible with other results summarized).
A diagnosis specific instrument for assessment of quality of life in achondroplasia has been developed [337, 339]. Called the “APLES” (Achondroplasia Personal Life Experience Scale) this could be of utility in the assessment of individuals (older children and young adults) with achondroplasia compared with their diagnostically identical peers.
Other than anecdotes, case reports and small series [344, 345], there is very little in the literature regarding risks and management of pregnancy in women who have achondroplasia. A questionnaire survey of a convenience sample of 87 women  allows some tentative conclusions to be drawn. Most women with achondroplasia have near-normal trunk size, which is likely the reason that most can carry pregnancies to term. Pregnancy-related complications are uncommon; the most serious of these seem to be worsening spinal claudication symptoms and, rarely, respiratory failure  (and personal observations). Risk for cardiorespiratory problems is probably increased in those who are of very small stature and have shorter than typical trunks, in those with severe spinal deformity, and in those who have had apnea-associated complications in their past.
The possibility of respiratory problems should be addressed early in every pregnancy of women with achondroplasia. It is prudent to complete baseline pulmonary function testing early in pregnancy and to involve a pulmonologist so that, should respiratory issues arise, an expert with antecedent knowledge of the patient will be at hand. Rarely interruption of a pregnancy by termination (personal observation) or delivery prematurely  (and personal observations) may be necessary as a maternal life-saving measure.
All women with achondroplasia must be delivered by elective Cesarean section because of uniform narrowing of the pelvis and cephalopelvic disproportion . (Parenthetically, one wonders what happened in centuries past if a woman with achondroplasia became pregnant.) This should be a planned Cesarean delivery without a trial of labor. Anesthesia for this procedure remains both controversial and challenging. No consensus has arisen whether or when general, spinal or epidural anesthesia is preferable  and there is virtually no data upon which to base such a decision. Dubiel et al.  outline the anesthetic challenges related to the statural, airway, spinal, respiratory and neurologic features of achondroplasia that can make decision making regarding anesthetic care so challenging.
It has long been recognized that anatomic prenatal diagnosis of achondroplasia is difficult and usually not feasible prior to mid-pregnancy whether by radiography  or ultrasonography . The challenge of using ultrasound resulted in frequent missed diagnoses and misdiagnoses . While considerable advances have been made in technique and interpretation [351, 352], recognition of achondroplasia, particularly in sporadic cases, remains difficult.
Now, of course, prenatal diagnosis is accomplished principally through molecular testing. One circumstance in which it may be utilized is when both parents are affected by achondroplasia. They then have a 25% risk that any conceptus will be homozygous and likely to either die in utero or neonatally. The community of little people has, for the most part, embraced prenatal testing for this purpose, while rejecting consideration of termination if results show either heterozygous achondroplasia or average stature . The second scenario is when ultrasonographic investigations, either routine or for cause, suggest the presence of a short limb dwarfing disorder. In this circumstance it is critical to determine if achondroplasia (the most common of the short limb conditions) is or is not causal. This can be done either through direct analysis of FGFR3, as part of a skeletal dysplasia molecular panel, or using whole exome sequencing.
Possible future therapies
As understanding of the molecular processes underlying achondroplasia have become better understood, a number of suggestions for possible molecular pharmacologic therapy have emerged . Whether any of these ideas will eventually lead to effective therapy of achondroplasia is, of course, unknown.
The most advanced of these possible therapeutic options is investigation of a C-type natriuretic peptide (CNP) analog. CNP in many ways acts as a counterbalance to the effects of FGFR3 on the growth plate. Loss of function mutations of the CNP receptor (the transmembrane natriuretic peptide receptor – NPR-B) results in another, severe dwarfing disorder called acromesomelic dysplasia, type Maroteaux . This disorder is certainly not a mirror image of achondroplasia – sharing almost nothing phenotypically with it except for marked small stature. Nonetheless it was postulated that increasing CNP activity could counteract the excess negative signal of FGFR3 mutations. And, indeed that appears to be true . An analog was developed by BioMarin Pharmaceuticals that has greater stability, and animal experiments were begun using this peptide, called BMN-111 . BMN-11 l (now called Vosoritide by BioMarin) reversed the achondroplasia phenotype in the mouse model of this disorder  and appeared to enhance bone growth in normal cynomolgus monkeys, including increases in growth plate thickness and increase in lumbar vertebral foraminal size . CNP also seems to have beneficial effect on midfacial development . Human trials have begun (https://www.biomarin.com/products/pipeline/bmn-111/). In fact, currently these trials include an expanded phase 2 trial in infants and young children as well as active recruitment for a phase 3 trial (https://clinicaltrials.gov). Whether this will be effective long term, whether undesired consequences of counteracting FGFR3 function will arise, and how early in life it would need to be administered to have salutary effects on health are all still unknown. Likewise, the demonstration of elevation of CNP at baseline in those with achondroplasia suggest that there might be tissue resistance to CNP (and its analogs) that could complicate this therapy .
Many other suggested therapies are at various stages of investigation. Unal & Tugan  have suggested use of mesenchymal stem cells as a source for native CNP. Yamashita et al.  showed that statin treatment ‘rescued’ stem cells (correction of degraded cartilage formation) and a mouse model of achondroplasia (with significant recovery of bone growth). If such therapy was seriously to be considered, the long term safety of chronic administration of statins to children would need to be demonstrated . Recent studies raise questions about the mechanism whereby statins might have consequence on achondroplastic bone . Meclizine (an over the counter medication for motion sickness) improves long bone growth in a mouse model of achondroplasia, apparently through inhibition of activity of downstream effectors of FGFR3 [370, 371, 372]. Apparently a phase I clinical trial of meclizine will commence shortly (http://www.growingstronger.org/).
Inhibition of chaperone proteins of FGFR3, which inhibition can result in ubiquitination and degradation of FGFR3 and, in turn, decreased signaling ;
Use of a small molecular inhibitor (tubacin) of histone deacetylase 6 which results in reduced accumulation of FGFR3 at the growth plate ;
Direct blocking of the FGFR3 binding domain ;
Reducing the activity of FGFR3 using a tyrosine kinase inhibitor .
Is the future now? Many individuals within the small stature community would embrace treatments that will eliminate some of the medical consequences of achondroplasia summarized here, while at the same time showing little or no enthusiasm for treatments exclusively or primarily aimed at linear growth enhancement.
A great deal has been learned about the consequences of achondroplasia on those who are affected. Nonetheless, the quality of care that can be provided is compromised by the limited quality of the evidence that is, for the most part, available. Although the future may include pathway driven therapies, there will remain a need for quality clinical investigations regarding the natural history and optimal interventions for the sequelae of achondroplasia.
I thank: all of the families who have contributed to my understanding of achondroplasia and its consequences; those from whom I learned so much about both achondroplasia and caring, including Dr. Leonard O. Langer Jr. (deceased) and Dr. Alan Breed; current and past members of the Midwest Regional Bone Dysplasia Clinic, particularly Peggy Modaff, M.S., Casey Reiser, M.S. and Janet Legare, M.D.; dozens of colleagues and collaborators both at the University of Wisconsin – Madison and elsewhere.
Cost of publication has been partially offset by the Department of Pediatrics, University of Wisconsin.
Availability of data and materials
Single author. The author read and approved the final manuscript.
Ethics approval and consent to participate
No new human data is used in this review and therefore no ethics approval is applicable.
Consent for publication
Written informed consent was obtained from individuals or their guardians for publication of all recognizable images. A copy of those written consents is available for review by the Editor-in-Chief of this journal.
The author declares that he has no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 4.Pauli RM, Botto LD. Achondroplasia. In: Cassidy SB, Battaglia A, Carey J, Viskochil DH, editors. Management of Genetic Syndromes. 4th ed. New York: Wiley; 2018. in press.Google Scholar
- 7.Pauli RM, Legare J. Achondroplasia. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, editors. GeneReviews; 2018.Google Scholar
- 10.Hoover-Fong JE, Bober M, Hashmi S, Hecht J, Legare J, Little M, McGready J, Pauli R, Schulze K, Serna E, Smid C, Alade AY. Achondroplasia natural history: the power of a multi-center clinical study. Bruges: International Skeletal Dysplasia Society; 2017.Google Scholar
- 11.Enderle A, Meyerhöfer D, Unverfehrt G. Small people-great art. Restricted growth from an artistic and medical viewpoint. Hamm: Artcolor; 1994.Google Scholar
- 31.Gomes MES, Kanazawa TY, Riba FR, Pereira NG, Zuma MCC, Rabelo NC, Sanseverino MT, Horovitz DDG, Lierena JC, Cavalcanti DP, Gonzalez S. Novel and recurrent mutations in the FGFR3 gene and double heterozygosity cases in a cohort of Brazilian patients with skeletal dysplasia. Mol Syndromol. 2018;9:92–9.PubMedPubMedCentralCrossRefGoogle Scholar
- 34.Langer LO, Schaefer GB, Wadsworth DT. Patient with double heterozygosity for achondroplasia and pseudoachondroplasia with comments on these conditions and the relationship between pseudoachondroplasia and multiple epiphyseal dysplasia, Fairbank type. Am J Med Genet. 1993;47:772–81.PubMedCrossRefPubMedCentralGoogle Scholar
- 36.De Azeveido Moreira LM, Matos MA, Schiper PP, Carvalho AFL, Gomes IC, Rolemberg JC, Ferreira de Lima RLL, Toralles MBP. Co-occurrence of achondroplasia and Down syndrome: genotype/phenotype association. Birth Defects Res A Clin Mol Teratol. 2010;88:228–31.Google Scholar
- 37.Kaga A, Murotsuki J, Kamimura M, Kimura M, Saito-Hakoda A, Kanno J, Hoshi K, Kure S, Fujiwara I. Association of achondroplasia with Down syndrome: difficulty in prenatal diagnosis by sonographic and 3-D helical computed tomographic analyses. Congenit Anom (Kyoto). 2015;55:116–20.CrossRefGoogle Scholar
- 54.Krejci P, Salazar L, Kashiwada TA, Chlebova K, Salasova A, Thompson LM, Bryja V, Kozubik A, Wilcox WR. Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal dysplasia undermines dominant role of STAT1 in FGFR3 signaling in cartilage. PLoS One. 2008;3:e3962–Epub.CrossRefGoogle Scholar
- 57.Wilkin DJ, Szabo JK, Cameron R, Henderson S, Bellus GA, Mack ML, Kaitila I, Loughlin J, Munnich A, Sykes B, Bonaventure J, Francomano CA. Mutations in fibroblast growth-factor receptor 3 in sporadic cases of achondroplasia occur exclusively on the paternally derived chromosome. Am J Hum Genet. 1998;63:711–6.PubMedPubMedCentralCrossRefGoogle Scholar
- 68.Heuertz S, Le Merrer M, Zabel B, Wright M, Legeai-Mallet L, Cormier-Daire V, Gibbs L, Bonaventure J. Novel FGFR3 mutations creating cysteine residues in the extraceullular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. Eur J Hum Genet. 2006;14:1240–7.PubMedCrossRefPubMedCentralGoogle Scholar
- 73.Kozlowski K, Barkowiak K. Hypochondroplasia. Pediatr Polska. 1965;40:379–89.Google Scholar
- 75.Hall JG. Hypochondroplasia. Birth Defects Orig Artic Ser. 1969;5(4):262–72.Google Scholar
- 76.Dorst JP. Hypochondroplasia. Birth Defects Orig Artic Ser. 1969;5(4):260–2.Google Scholar
- 77.Murdoch JL. Hypochondroplasia. Birth Defects Orig Artic Ser. 1969;5(4):273–6.Google Scholar
- 79.Langer LO. Hypochondroplasia. In: Bergsma D, editor. Birth defects atlas and compendium. Baltimore: Williams and Wilkins; 1973. p. 513–4.Google Scholar
- 81.Kant SG, Cervenkova I, Balek L, Trantirek L, Santen GWE, De Vries MC, van Duyvenvoorde HA, van der Wielen MJR, Verkerk JMH, Uitterlinden AG, Hannema SE, Wit JM, Oostdijk W, Krejci P, Losekoot M. A novel variant of FGFR3 causes proportionate short stature. Eur J Endocrinol. 2015;172:763–70.PubMedCrossRefPubMedCentralGoogle Scholar
- 82.Bober MB, Bellus GA, Nikkel SM, Tiller GE. Hypochondroplasia. In: Pagon RA, Adam MP, Ardinger HH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K; GeneReviews; 2013.Google Scholar
- 88.Maroteaux P, Lamy M, Robert J-M. Le nanisme thanatophore. Presse Med. 1967;49:2519–24.Google Scholar
- 92.Tavormina PL, Bellus GA, Webster MK, Bamshad MJ, Fraley AE, McIntosh I, Szabo J, Jiang W, Jabs EW, Wilcox WR, Wasmuth JJ, Donohue DJ, Thompson LM, Francomano CA. A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene. Am J Hum Genet. 1999;64:722–31.PubMedPubMedCentralCrossRefGoogle Scholar
- 93.Bellus GA, Bamshad MJ, Przylepa KA, Dorst J, Lee RR, Hurko O, Jabs EW, Curry CJ, Wilcox WR, Lachman RS, Rimoin DL, Francomano CA. Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3. Am J Med Genet. 1999;85:53–65.PubMedCrossRefPubMedCentralGoogle Scholar
- 110.Hashmi SS, Gamble C, Hoover-Fong J, Alade A, Pauli RM, Modaff P, Carney M, Brown C, Bober MB, Hecht JT. Multi-center study of mortality in achondroplasia. Am J Med Genet A. 2018. https://doi.org/10.1002/ajmg.a.40528.
- 111.Pauli RM, Lebovitz RM. Apnea and sudden infant death: are children with achondroplasia at increased risk? D.W. Smith Conference on Malformations and Morphogenesis, Hickory Knob, SC; 1982.Google Scholar
- 113.Pauli RM, Scott CI, Wassman ER, Gilbert EF, Leavitt LA, Ver Hoeve J, Hall JG, Partington MW, Jones KL, Sommer A, Feldman W, Langer LO, Rimoin DL, Hecht JT, Lebovitz R. Apnea and sudden unexpected death in infants with achondroplasia. J Pediatr. 1984;104:342–8.PubMedCrossRefPubMedCentralGoogle Scholar
- 117.Matsushita T, Wilcox WR, Chan YY, Kawanami A, Bükülmez H, Balmes G, Krejci P, Mekikian PB, Otani K, Yamaura I, Warman ML, Givol D, Murakami S. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway. Hum Mol Genet. 2009;18:227–40.PubMedCrossRefPubMedCentralGoogle Scholar
- 120.Sano M, Takahashi N, Nagasaki K, Oishi M, Yoshimura J, Fujii Y. Polysomnography as an indicator for cervicomedullary decompression to treat foramen magnum stenosis in achondroplasia. Childs Nerv Syst. 2018. https://doi.org/10.1007/s00381-018-3880-0 [Epub ahead of print].
- 128.Brühl K, Stoeter P, Wietek B, Schwarz M, Himpl T, Schumacher R, Spranger J. Cerebral spinal fluid flow, venous drainage and spinal cord compression in achondroplastic children: impact of magnetic resonance findings for decompressive surgery at the craniocervical junction. Eur J Pediatr. 2001;160:10–20.PubMedCrossRefPubMedCentralGoogle Scholar
- 129.Mukherjee D, Pressman BD, Krakow D, Rimoin DL, Danielpour M. Dynamic cervicomedullary cord compression and alterations in cerebrospinal fluid dynamics in children with achondroplasia: review of an 11-year surgical case series. J Neurosurg Pediatr. 2014;14:238–43.PubMedCrossRefPubMedCentralGoogle Scholar
- 134.White KK, Bompadre V, Goldberg MJ, Bober MB, Campbell JW, Cho T-J, Hoover-Fong J, Mackenzie W, Parnell SE, Raggio C, Rapoport DM, Spencer SA, Savarirayan R. Best practices in the evaluation and treatment of foramen magnum stenosis in achondroplasia during infancy. Am J Med Genet A. 2015;170A:42–51.PubMedGoogle Scholar
- 144.King JA, Vachhrajani S, Drake JM, Rutka JT. Neurosurgical implications of achondroplasia. J NeurosurgPediatr. 2009;4:297–306.Google Scholar
- 147.Ireland PJ, Johnson S, Donaghey S, Johnston L, Ware RS, Zanki A, Pacey V, Ault J, Savarirayan R, Sillence D, Thompson E, Townshend S, McGill J. Medical management of children with achondroplasia: evaluation of an Australasian cohort aged 0-5 years. J Paediatr Child Health. 2012;48:443–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 154.Hoover-Fong J, McGready J, Schulze K, Alade AY, Scott CI. A height-for-age growth reference for children with achondroplasia: expanded applications and comparison with original reference data. Am J Med Genet A. 2016;173A:1226–30.Google Scholar
- 156.Greenwood Genetics Center. Growth references from conception to adulthood. Clinton: Jacobs; 1988.Google Scholar
- 164.Hertel NT, Eklöf O, Ivarsson S, Aronson S, Westphal O, Sipila I, Kaitila I, Bland J, Veimo D, Müller J, Mohnike K, Neumeyer L, Ritzen M, Hagenäs L. Growth hormone treatment in 35 prepubertal children with achondroplasia: a five-year dose-response trial. Acta Paediatr. 2005;94:1402–10.PubMedCrossRefGoogle Scholar
- 167.Villarubias JM, Ginebreda I, Jimeno E. Lengthening of the lower limbs and correction of lumbar hyperlordosis in achondroplasia. Clin Orthop Relat Res. 1990;(250):143–9.Google Scholar
- 171.Little People of America Medical Advisory Board. 2006. http://www.lpaonline.org/ell-position-statement. Accessed 16 Sept 2018.
- 178.Carneiro JRI, da Silveira VG, Vasconcelos CAN, de Souza LL, Xerez D, da Cruz GG, Quaresma JCV, Macedo RGA, de Oliveira JEP. Bariatric surgery in a morbidly obese achondroplasic patient – use of the 6-minute walk test to assess mobility and quality of life. Obes Surg. 2007;17:255–7.PubMedCrossRefPubMedCentralGoogle Scholar
- 185.Ireland PJ, Johnson S, Donaghey S, Johnston L, McGill J, Zankl A, Ware RS, Pacey V, Ault J, Savarirayan R, Sillence D, Thompson E, Townshend S. Developmental milestones in infants and young Australasian children with achondroplasia. J Dev Behav Pediatr. 2010;31:41–7.PubMedCrossRefPubMedCentralGoogle Scholar
- 187.Ireland PJ, Ware RS, Donaghey S, McGill J, Zankl A, Pacey V, Ault J, Savarirayan R, Sillence D, Thompson E, Townshend S, Johnston LM. The effect of height, weight and head circumference on gross motor development in achondroplasia. J Paediatr Child Health. 2013;49:E122–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 189.Galasso C, Siracusano M, El Malhany N, Cerminara C, Pitzianti M, Terribili M. Cognitive phenotype and language skills in children with achondroplasia. Minerva Pediatr. 2016; Epub ahead of print.Google Scholar
- 190.Baraboo M. Neurobehavior in achondroplasia: Is there an increased risk for pervasive developmental disorders? Unpublished thesis, University of Wisconsin – Madison, Department of Medical Genetics; 2003.Google Scholar
- 205.Hecht JT, Bodensteiner JB, Butler IJ. Neurological manifestation of achondroplasia. In: Biller J, Ferro JM, editors. Handbook of clinical neurology, vol 119, part 1: chapter 36. Amsterdam: Elsevier; 2014. p. 551–63.Google Scholar
- 207.Blondeau M, Brunet D, Blanche JM, DeBauchez C, Etienne M. Compression de la moelle cervicale dans l’achondroplasie a propos de deux observations chez le nourrisson. Ann Pediatr. 1983;30:651–6.Google Scholar
- 213.Rahimizadeh A, Soufiani HF, Hassani V, Rahimizadeh A. Atlantoaxial subluxation due to an os odontoideum in an achondroplasitc adult: report of a case and review of the literature. Case Rep Orthop. 2015:142586. https://doi.org/10.1155/2015/142586.
- 214.Dixit SN, Sheth RD, Pauli RM. Epilepsy in patients with achondroplasia and related disorders associated with FGFR3 mutations. Los Angeles: American Epilepsy Society; 2000.Google Scholar
- 219.Afsharpaiman S, Saburi A, Waters KA. Respiratory difficulties and breathing disorders in achondroplasia. Paediatr Resp Rev. 2011;14:250–5.Google Scholar
- 223.O’Brien LM. Cognitive and behavioral consequences of obstructive sleep apnea. In: Sheldon SH, Ferber R, Kryger MH, Gozal D, editors. Principles & practice of pediatric sleep medicine. 2nd ed. London: Elsevier; 2014. p. 231–8.Google Scholar
- 225.Strohl KP, Brown DB, Collop N, George C, Grunstein R, Han F, Kline L, Malhotra A, Pack A, Phillips B, Rodenstein D, Schwab R, Weaver T, Wilson K, ATS Ad Hoc Committee on Sleep Apnea, Sleepiness, and Driving Risk in Noncommercial Drivers. An official American Thoracic Society Clinical Practice Guideline: sleep apnea, sleepiness, and driving risk in noncommercial drivers. An update of a 1994 statement. Am J Respir Crit Care Med. 2013;187:1259–66.PubMedPubMedCentralCrossRefGoogle Scholar
- 237.Sudaram S, Bridgman SA, Lim J, Lasserson TJ. Surgery for obstructive sleep apnoea. Cochrane Database Syst Rev. 2005;19:CD001004.Google Scholar
- 241.Crawford DB, Ensor RE, Dorst JP. The chondrocranium in achondroplasia. In: Bosma JF, editor. Development of the basicranium. Bethesda: U.S. Department of Health, Education and Welfare Publication NIH 76–989; 1976. p. 301–8.Google Scholar
- 249.Wheeldon T. A study of achondroplasia: introducing a new symptom, a wedge shaped vertebra. Am J Dis Child. 1920;19:1–37.Google Scholar
- 250.Donath J, Vogl A. Untersuchungen über den chondrodystrophischen Zwergwuchs: das Verhalten der Wirbelsäule beim chondrodystrophischen Zwerg. Wien Arch Finn Med. 1925;10:1–44.Google Scholar
- 253.Borkhuu B, Nagaraju DK, Chan G, Holmes L, Mackenzie WG. Factors related to progression of thoracolumbar kyphosis in children with achondroplasia: a retrospective cohort study of forty-eight children treated in a comprehensive orthopaedic center. Spine. 2009;34:1699–705.PubMedCrossRefPubMedCentralGoogle Scholar
- 254.Lonstein JE. Treatment of kyphosis and lumbar stenosis in achondroplasia. Basic Life Sci. 1988;48:282–92.Google Scholar
- 259.Margalit A, McKean G, Lawing C, Galey S, Ain MC. Walking out of the curve: thoracolumbar kyphosis in achondroplasia. J Pediatr Orthop. 2016; epub ahead of print.Google Scholar
- 260.Xu L, Li Y, Sheng F, Xia C, Qiu Y, Zhu Z. The efficacy of brace treatment for thoracolumbar kyphosis in patients with achondroplasia. Spine. 2018; epub ahead of print.Google Scholar
- 265.Lutter LD, Lonstein JE, Winter RB, Langer LO. Anatomy of the achondroplastic lumbar canal. Clin Orthop. 1977;127:139–42.Google Scholar
- 277.Kopits SE. Lower limb deformities in dwarfism. J Bone Joint Surg A. 1975;75:A1172.Google Scholar
- 278.Kopits SE. Orthopedic complications of dwarfism. Clin Orthop Relat Res. 1976;114:153–79.Google Scholar
- 289.Stanley G, McLoughlin S, Beals RK. Observations on the cause of bowlegs in achondroplasia. J Pediatr Orthop. 1970;21:112–6.Google Scholar
- 305.Cohen MM, Walker GF, Phillips C. A morphometric analysis of the craniofacial configuration in achondroplasia. J Craniofac Genet Dev Biol. 1985;1(Suppl):139–65.Google Scholar
- 317.Smid CJ, Modaff P, Alade A, Legare JM, Pauli RM. Acanthosis nigricans in achondroplasia. Am J Med Genet A. 2018:e40506. https://doi.org/10.1002/ajmg.a.40506.
- 320.Castro-Feijóo L, Loidi L, Vidal A, Parajes S, Rosón E, Alvarez A, Cabanas P, Barreiro J, Alonso A, Domínguez F, Pombo M. Hypochondroplasia and acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor type 3 gene? Eur J Endocrinol. 2008;159:243–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 329.Accogli A, Paetti M, Fiaschi P, Pavanello M, Piatelli G, Nuzzi D, Baldi M, Tassano E, Severino MS, Allegri A, Capra V. Association of achondroplasia with sagittal synostosis and scaphocephaly in two patients, an underestimated condition? Am J Med Genet A. 2015;167A:646–52.PubMedCrossRefPubMedCentralGoogle Scholar
- 336.Rohenkohl AC, Sommer R, Bestges S, Kahrs S, Klingebiel K-H, Bullinger M, Quitmann M. Leben mit Achondroplasies. Wie beurteilen junge Menschen mit disproportioniertem Kleinwuchs ihre Lebensqualität und mit welchen Faktoren ist sie assoziiert? Z Kinder Jugendpsychiatr Psychother. 2015;43:433–41.PubMedCrossRefPubMedCentralGoogle Scholar
- 337.Sommer R, Blömeke J, Dabs M, Witt S, Bullinger M, Quitmann J. An ICF-CY-based approach to assessing self- and observer-reported functioning in young persons with achondroplasia – development of the pilot version of the Achondroplasia Personal Life Experience Scale (APLES). Disabil Rehabil. 2017;39:2499–503.PubMedCrossRefPubMedCentralGoogle Scholar
- 338.Witt S, Rohenkohl A, Bullinger M, Sommer R, Kahrs S, Klingebiel K-H, Klingebiel R, Quitmann J. Understanding, assessing and improving health-related quality of life of young people with achondroplasia – a collaboration between a patient organization and academic medicine. Pediatr Endo Rev. 2017;15(suppl 1):109–18.Google Scholar
- 339.Bloemeke J, Sommer R, Witt S, Dabs M, Badia FJ, Bullinger M, Quitmann J. Piloting and psychometric properties of a patient-reported outcome instrument for young people with achondroplasia based on the International Classification of Functioning, Disability and Health: the Achondroplasia Personal Life Experience Scale (APLES). Disabil Rehabil. 2018;8:1–11.CrossRefGoogle Scholar
- 352.Hatzaki A, Sifakis S, Apostolopoulou D, Bouzarelou D, Konstantinidou A, Kappou D, Sideris A, Tzortzi E, Athanassiadis A, Florentin L, Theodoropoulos P, Makatsoris C, Karadimas C, Velissariou V. FGFR3 related skeletal dysplasias diagnosed prenatally by ultrasonography and molecular analysis: presentation of 17 cases. Am J Med Genet A. 2011;155:2426–35.CrossRefGoogle Scholar
- 354.Chitty LS, Griffin DR, Meaney C, Barrett A, Khalil A, Pajkrt E, Cole TJ. New aids for the non-invasive prenatal diagnosis of achondroplasia: dysmorphic features, charts of fetal size and molecular confirmation using cell-free fetal DNA in maternal plasma. Ultrasound Obstet Gynecol. 2011;37:283–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 355.Chitty LS, Mason S, Barrett AN, McKay F, Lench N, Daley R, Jenkins LA. Non-invasive prenatal diagnosis of achondroplasia and thanatophoric dysplasia: next-generation sequencing allows for a safer, more accurate, and comprehensive approach. Prenat Diagn. 2015;35:656–62.PubMedPubMedCentralCrossRefGoogle Scholar
- 356.Orhant L, Anselem O, Fradin M, Becker PH, Beugnet C, Deburgrave N, Tafuri G, Letourneur F, Goffinet F, Allach El Khattabi L, Leturcq F, Benvenu T, Tsatsaris V, Nectoux J. Droplet digital PCR combined with minisequencing, a new approach to analyze fetal DNA from maternal blood: application to the non-invasive prenatal diagnosis of achondroplasia. Prenat Diagn. 2016;36:397–406.PubMedCrossRefPubMedCentralGoogle Scholar
- 357.Chen J, Yu C, Zhao Y, Niu Y, Zhang L, Yu Y, Wu J, He J. A novel non-invasive detection method for the FGFR3 gene mutation in maternal plasma for a fetal achondroplasia diagnosis based on signal amplification by hemin-MOFsPtNPs. Biosens Bioelectron. 2017;91:892–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 358.Terasawa S, Kato A, Nishizawa H, Kato T, Yoshizawa H, Noda Y, Miyazaki J, Ito M, Sekiya T, Fujii T, Kurahashi H. Multiplex PCR in noninvasive prenatal diagnosis for FGFR3-related disorders. Congenit Anom (Kyoto). 2018. https://doi.org/10.1111/cga.12278 epub ahead of print.
- 360.Bartels CF, Bükülmez H, Padayatti P, Rhee DK, van Ravenswaaij-Arts C, Pauli RM, Mundlos S, Chitayat D, Shih LY, Al-Gazali LI, Kant S, Cole T, Morton J, Cormier-Daire V, Faivre L, Lees M, Kirk J, Mortier GR, Leroy J, Zabel B, Kim CA, Crow Y, Braverman NE, van den Akker F, Warman ML. Mutations in the transmembrane natriuretic peptide receptor NPR-B impair skeletal growth and cause acromesomelic dysplasia, type Maroteaux. Am J Hum Genet. 2004;75:27–34.PubMedPubMedCentralCrossRefGoogle Scholar
- 362.Wendt DJ, Dvorak-Ewell M, Bullens S, Lorget F, Bell SM, Peng J, Castillo S, Aoyagi-Scharber M, O’Neill CA, Krejci P, Wilcox WR, Rimoin DL, Bunting S. Neutral endopeptidase resistant C-type natriuretic peptide (CNP) variant represent a new therapeutic approach for treatment of fibroblast growth factor receptor 3 – related dwarfism. J Pharmacol Exp. 2015;353:132–49.CrossRefGoogle Scholar
- 363.Lorget F, Kaci N, Peng J, Benoist-Lasselin C, Mugniery E, Oppeneer T, Wendt DJ, Bell SM, Bullens S, Bunting S, Tsuruda LS, O’Neill CA, Di RF, Munnich A, Legeai-Mallet L. Evaluation of the therapeutic potential of a CNP analog in a Fgfr3 mouse model recapitulating achondroplasia. Am J Hum Genet. 2012;91:1108–14.PubMedPubMedCentralCrossRefGoogle Scholar
- 365.Olney RC, Prickett TC, Espiner EA, Mackenzie WG, Duker AL, Ditro C, Zabel B, Hasegawa T, Kitoh H, Aylsworth AS, Bober MB. C-type natriuretic peptide plasma levels are elevated in subjects with achondroplasia, hypochondroplasia and thanatophoric dysplasia. J Clin Endocrinol Metab. 2015;100:E355–9.PubMedCrossRefPubMedCentralGoogle Scholar
- 368.Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2014;7:CD006401.Google Scholar
- 370.Matsushita M, Esaki R, Mishima K, Ishiguro N, Ohno K, Kitoh H. Clinical dosage of meclizine promotes longitudinal bone growth, bone volume, and trabecular bone quality in transgenic mice with achondroplasia. Sci Rep. 2017;7:7371. https://doi.org/10.1038/s41598-017-07044-8.CrossRefPubMedPubMedCentralGoogle Scholar
- 372.Matsushita M, Kitoh H, Ohkawara B, Mishima K, Kaneko H, Ito M, Masuda A, Ishiguro N, Ohno K. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia. PLoS One. 2013;8:e81569.PubMedPubMedCentralCrossRefGoogle Scholar
- 376.Jin M, Yu Y, Qi H, Xie Y, Su N, Wang X, Tan Q, Luo F, Zhu Y, Wang Q, Du X, Xian CJ, Liu P, Huang H, Shen Y, Deng CX, Chen D, Chen L. A novel FGFR3-binding peptide inhibits FGFR3 signaling and reverses the lethal phenotype of mice mimicking human thanatophoric dysplasia. Hum Mole Genet. 2012;21:5443–55.CrossRefGoogle Scholar
- 377.Komla-Ebri D, Dambroise E, Kramer I, Benoist-Lasselin C, Kaci N, Le Gall C, Martin L, Busca P, Barbault F, Graus-Porta D, Munnich A, Kneissel M, Di Rocco F, Biosse-Duplan M, Legeai-Mallet L. Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model. J Clin Invest. 2016;126:1871–84.PubMedPubMedCentralCrossRefGoogle Scholar
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.